<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia - Wang, Q - 2017 | Cochrane Library</title> <meta content="Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia - Wang, Q - 2017 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007289.pub3/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia - Wang, Q - 2017 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007289.pub3/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD007289.pub3" name="dc.identifier" scheme="DOI"/> <meta content="Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia" name="citation_title"/> <meta content="Qiuyi Wang" name="citation_author"/> <meta content="West China Second University Hospital, West China Women's and Children's Hospital" name="citation_author_institution"/> <meta content="Jing Fu" name="citation_author"/> <meta content="fujing23@gmail.com" name="citation_author_email"/> <meta content="Lina Hu" name="citation_author"/> <meta content="The Second Affiliated Hospital of Chongqing Medical University" name="citation_author_institution"/> <meta content="Fang Fang" name="citation_author"/> <meta content="West China Second University Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Lingxia Xie" name="citation_author"/> <meta content="West China Second University Hospital, West China Women's and Children's Hospital" name="citation_author_institution"/> <meta content="Hengxi Chen" name="citation_author"/> <meta content="West China Second University Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Fan He" name="citation_author"/> <meta content="The Second Affiliated Hospital of Chongqing Medical University" name="citation_author_institution"/> <meta content="Taixiang Wu" name="citation_author"/> <meta content="West China Hospital, Sichuan University" name="citation_author_institution"/> <meta content="Theresa A Lawrie" name="citation_author"/> <meta content="The Evidence‐Based Medicine Consultancy Ltd" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="9" name="citation_issue"/> <meta content="10.1002/14651858.CD007289.pub3" name="citation_doi"/> <meta content="2017" name="citation_date"/> <meta content="2017/09/11" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007289.pub3/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007289.pub3/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD007289.pub3/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Antineoplastic Agents [*therapeutic use]; Dactinomycin [*therapeutic use]; Gestational Trophoblastic Disease [epidemiology, *prevention &amp; control]; Hydatidiform Mole [*drug therapy]; Incidence; Methotrexate [*therapeutic use]; Randomized Controlled Trials as Topic" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD007289.pub3&amp;doi=10.1002/14651858.CD007289.pub3&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="1ljSZou6";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD007289\x2epub3\x26doi\x3d10\x2e1002\x2f14651858\x2eCD007289\x2epub3\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ko","ms","hr","fa","ja"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD007289.pub3",title:"Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia",firstPublishedDate:"Sep 11, 2017 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Gynaecological, Neuro‐oncology and Orphan Cancer Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007289.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007289.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD007289.pub3/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD007289.pub3/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007289.pub3%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD007289.PUB3" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;초록&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;hr&quot;,&quot;title&quot;:&quot;Laički sažetak&quot;},{&quot;language&quot;:&quot;ja&quot;,&quot;title&quot;:&quot;一般語訳&quot;},{&quot;language&quot;:&quot;ko&quot;,&quot;title&quot;:&quot;쉬운 말 요약&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD007289.pub3/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD007289.PUB3" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD007289.pub3/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD007289.pub3/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>6473 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD007289.pub3" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-abs-0005"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-sec-0091"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-sec-0057"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-sec-0078"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/appendices#CD007289-sec-0096"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/table_n/CD007289StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/table_n/CD007289StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2019 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Prophylactic chemotherapy for hydatidiform mole to prevent gestational trophoblastic neoplasia </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#CD007289-cr-0002">Qiuyi Wang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#CD007289-cr-0003"><i class="icon corresponding-author fa fa-envelope"></i>Jing Fu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#CD007289-cr-0004">Lina Hu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#CD007289-cr-0005">Fang Fang</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#CD007289-cr-0006">Lingxia Xie</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#CD007289-cr-0007">Hengxi Chen</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#CD007289-cr-0008">Fan He</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#CD007289-cr-0009">Taixiang Wu</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information#CD007289-cr-0010">Theresa A Lawrie</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information/en#CD007289-sec-0102">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 11 September 2017 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD007289.pub3">https://doi.org/10.1002/14651858.CD007289.pub3</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD007289-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007289-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007289-abs-0004">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007289-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007289-abs-0002">한국어</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD007289-abs-0001" lang="en"> <section id="CD007289-sec-0001"> <h3 class="title" id="CD007289-sec-0001">Background</h3> <p>This is an update of the original Cochrane Review published in Cochrane Library, Issue 10, 2012. </p> <p>Hydatidiform mole (HM), also called a molar pregnancy, is characterised by an overgrowth of foetal chorionic tissue within the uterus. HMs may be partial (PM) or complete (CM) depending on their gross appearance, histopathology and karyotype. PMs usually have a triploid karyotype, derived from maternal and paternal origins, whereas CMs are diploid and have paternal origins only. Most women with HM can be cured by evacuation of retained products of conception (ERPC) and their fertility preserved. However, in some women the growth persists and develops into gestational trophoblastic neoplasia (GTN), a malignant form of the disease that requires treatment with chemotherapy. CMs have a higher rate of malignant transformation than PMs. It may be possible to reduce the risk of GTN in women with HM by administering prophylactic chemotherapy (P‐Chem). However, P‐Chem given before or after evacuation of HM to prevent malignant sequelae remains controversial, as the risks and benefits of this practice are unclear. </p> </section> <section id="CD007289-sec-0002"> <h3 class="title" id="CD007289-sec-0002">Objectives</h3> <p>To evaluate the effectiveness and safety of P‐Chem to prevent GTN in women with a molar pregnancy. To investigate whether any subgroup of women with HM may benefit more from P‐Chem than others. </p> </section> <section id="CD007289-sec-0003"> <h3 class="title" id="CD007289-sec-0003">Search methods</h3> <p>For the original review we performed electronic searches in the Cochrane Gynaecological Cancer Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 2, 2012), MEDLINE (1946 to February week 4, 2012) and Embase (1980 to 2012, week 9). We developed the search strategy using free text and MeSH. For this update we searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 5, 2017), MEDLINE (February 2012 to June week 1, 2017) and Embase (February 2012 to 2017, week 23). We also handsearched reference lists of relevant literature to identify additional studies and searched trial registries. </p> </section> <section id="CD007289-sec-0004"> <h3 class="title" id="CD007289-sec-0004">Selection criteria</h3> <p>We included randomised controlled trials (RCTs) of P‐Chem for HM.</p> </section> <section id="CD007289-sec-0005"> <h3 class="title" id="CD007289-sec-0005">Data collection and analysis</h3> <p>Two review authors independently assessed studies for inclusion in the review and extracted data using a specifically designed data collection form. Meta‐analyses were performed by pooling data from individual trials using Review Manager 5 (RevMan 5) software in line with standard methodological procedures expected by Cochrane methodology. </p> </section> <section id="CD007289-sec-0006"> <h3 class="title" id="CD007289-sec-0006">Main results</h3> <p>The searches identified 161 records; after de‐duplication and title and abstract screening 90 full‐text articles were retrieved. From these we included three RCTs with a combined total of 613 participants. One study compared prophylactic dactinomycin to no prophylaxis (60 participants); the other two studies compared prophylactic methotrexate to no prophylaxis (420 and 133 participants). All participants were diagnosed with CMs. We considered the latter two studies to be of poor methodological quality. </p> <p>P‐Chem reduced the risk of GTN occurring in women following a CM (3 studies, 550 participants; risk ratio (RR) 0.37, 95% confidence interval (CI) 0.24 to 0.57; I² = 0%; P &lt; 0.00001; low‐quality evidence). However, owing to the poor quality (high risk of bias) of two of the included studies, we performed sensitivity analyses excluding these two studies. This left only one small study of high‐risk women to contribute data for this primary outcome (59 participants; RR 0.28, 95% CI 0.10 to 0.73; P = 0.01); therefore we consider this evidence to be of low quality. </p> <p>The time to diagnosis was longer in the P‐Chem group than the control group (2 studies, 33 participants; mean difference (MD) 28.72, 95% CI 13.19 to 44.24; P = 0.0003; low‐quality evidence); and the P‐Chem group required more courses to cure subsequent GTN (1 poor‐quality study, 14 participants; MD 1.10, 95% CI 0.52 to 1.68; P = 0.0002; very low quality evidence). </p> <p>There were insufficient data to perform meta‐analyses for toxicity, overall survival, drug resistance and reproductive outcomes. </p> </section> <section id="CD007289-sec-0007"> <h3 class="title" id="CD007289-sec-0007">Authors' conclusions</h3> <p>P‐Chem may reduce the risk of progression to GTN in women with CMs who are at a high risk of malignant transformation; however, current evidence in favour of P‐Chem is limited by the poor methodological quality and small size of the included studies. As P‐Chem may increase drug resistance, delays treatment of GTN and may expose women toxic side effects, this practice cannot currently be recommended. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD007289-abs-0005" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD007289-abs-0005">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD007289-abs-0010">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD007289-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/hr#CD007289-abs-0008">Hrvatski</a> </li> <li class="section-language"> <a class="" href="full/ja#CD007289-abs-0011">日本語</a> </li> <li class="section-language"> <a class="" href="full/ko#CD007289-abs-0006">한국어</a> </li> <li class="section-language"> <a class="" href="full/ms#CD007289-abs-0007">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD007289-abs-0005" lang="en"> <h3>Prophylactic (preventive) chemotherapy for hydatidiform mole (molar pregnancy) to prevent cancerous growth later </h3> <p><b>Background</b><br/> A molar pregnancy (hydatidiform mole) develops following an abnormal process of conception, whereby placental tissue overgrows inside the womb (uterus). Molar pregnancies are classified as complete (CM) or partial (PM) based on their appearance (gross and microscopic), and their chromosome pattern. When present, moles are usually suspected at the early pregnancy scan and women often present with bleeding, similar to a miscarriage. The molar tissue is removed by evacuation of retained products of conception (ERPC), also known as dilatation and curettage (D&amp;C) and women generally make a full recovery. However, some women go on to develop a cancer in the womb (about 1 in every 5 women with a CM and 1 in 200 with a PM). Women are generally at a higher risk of getting this cancer, which is known as gestational trophoblastic neoplasia (GTN), if they are over 40 years old, have a large increase in the size of the womb, have large cysts in the ovaries or have high initial levels of β‐human chorionic gonadotrophin (hCG) (the pregnancy hormone) in their blood. Although treatment of the cancer with chemotherapy (anti‐cancer drugs) is almost always effective, it has been suggested that routinely giving women anti‐cancer drugs (P‐Chem) before or after the removal the molar tissue may reduce the risk of the cancerous tissue developing. </p> <p><b>The aim of the review</b><br/> By doing this review, we tried to assess the benefits and risks of giving anti‐cancer drugs (P‐Chem) to women with molar pregnancies, before or after ERPC. </p> <p><b>What are the main findings?</b><br/> We found three randomised studies (randomised controlled trials (RCTs) where people are allocated at random i.e. by chance alone) involving a total of 613 women. Two studies tested methotrexate in all women with a CM and one study tested dactinomycin in women with a CM who were at a high risk of getting GTN. The two methotrexate studies are older studies that used relatively poor research methods, therefore their findings cannot be relied upon. Overall the review findings suggest that P‐Chem reduces the number of women developing cancer after molar pregnancy; however, this is probably only true for women with high‐risk moles (i.e. CM). In addition, P‐Chem might make the time to diagnose the cancer longer and might increase the number of anti‐cancer treatments needed to cure the cancer if it develops. We were unable to assess the short‐ and long‐term side‐effects of P‐Chem in this review because there were not enough available data; however, we are concerned that the five‐ and eight‐day courses of P‐Chem used by researchers in these studies are too toxic to be given to women routinely. </p> <p><b>Quality of the evidence</b><br/> We consider this evidence to be of a low to very low quality. This conclusion is based on our assessment that two of the included studies were of poor methodological quality and at a high risk of bias; the third study was of a good quality but consisted of only 60 participants. </p> <p><b>What are the conclusions?</b><br/> Currently there is insufficient evidence to support giving anti‐cancer drugs to women with molar pregnancies. However, GTN is almost always cured with modern care and P‐Chem for molar pregnancy would only reduce the risk of needing full‐scale chemotherapy, but would not remove that risk. In addition, it would not change the need for careful monitoring and follow‐up of women with hydatidiform moles. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD007289-sec-0091" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD007289-sec-0091"></div> <h3 class="title" id="CD007289-sec-0092">Implications for practice</h3> <section id="CD007289-sec-0092"> <p>P‐Chem may reduce the risk of progression to GTN in women with CMs who are at a high risk of malignant transformation. However, the five‐ and eight‐day methotrexate and dactinomycin regimens studied in this review were too toxic for routine use, may delay the time to GTN diagnosis and may lead to subsequent drug resistance. The current evidence in favour of P‐Chem is limited by the small numbers and poor methodological quality of available RCTs in this field. Hence there is currently insufficient evidence to support the use of P‐Chem in clinical practice. </p> </section> <h3 class="title" id="CD007289-sec-0093">Implications for research</h3> <section id="CD007289-sec-0093"> <p>One well‐conducted RCT of single‐dose dactinomycin compared with placebo for high‐risk CM may be appropriate in countries with limited healthcare resources and where follow‐up and hCG surveillance are more difficult. Baseline histology should be reported and outcomes should include: time to GTN diagnosis; HM and GTN risk scores at diagnosis; the number of courses to cure; long‐term survival; QoL; subsequent pregnancies; and an economic evaluation of the intervention groups over time. </p> <p>Other RCTs that may be helpful include:</p> <p> <ul id="CD007289-list-0005"> <li> <p>vitamin A studies (e.g. a 200,000 IU bolus or monthly) versus placebo, in women with a histological diagnosis of HM; </p> </li> <li> <p>second ERPC versus no additional (routine) ERPC in women with a histological diagnosis of HM. (There is currently a pilot Phase II study [GOG‐0242] underway to investigate the effect of a second ERPC in women with low‐risk GTN on the frequency of surgical cure and the rate of persistent GTN (<a href="./references#CD007289-bbs2-0009" title="Gynecologic Oncology Group. Second Curettage in Treating Patients With Persistent Non‐Metastatic Gestational Trophoblastic Tumor. NCT00521118. clinicaltrials.gov/ct2/show/NCT00521118?term=GOG‐0242&amp;rank=1 (accessed prior to 19 August 2017). ">GOG 0242</a>)). </p> </li> </ul> </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD007289-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD007289-sec-0029"></div> <div class="table" id="CD007289-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylactic chemotherapy compared with no prophylactic chemotherapy for hydatidiform mole</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: women with a molar pregnancy</b> </p> <p><b>Settings: inpatient</b> </p> <p><b>Intervention: methotrexate or dactinomycin</b> </p> <p><b>Comparison: placebo or no prophylaxis</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No prophylaxis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P‐Chem</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of GTN</b> </p> <p><b>(including low‐quality studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Mixed‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.37</b> (0.24 to 0.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>550 women<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The NNTB to prevent 1 woman developing GTN after evacuation of HM was 6 (95% CI 5 to 10). We downgraded this evidence because this meta‐analysis included 2 studies that we considered to be of poor methodological quality. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>254 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>94 per 1000</b> (61 to 145) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.29</b> </p> <p>(0.14 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>99 women</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>The NNTB for women with high‐risk HM was 3 (95% CI 2 to 5). We downgraded this evidence because the meta‐analysis included 2 small studies, 1 of which was of a poor methodological quality. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>490 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>142 per 1000 (69 to 294)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Incidence of GTN</b> </p> <p><b>(excluding low‐quality studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.28 (</b>0.10 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>59 women</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>The NNTB to prevent 1 woman developing GTN after evacuation of high‐risk HM was 3 (95% CI 2 to 20). We downgraded this evidence because only 1 small study (<a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>) contributed data, giving an imprecise result. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>140 per 1000</b> (50 to 365) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to GTN diagnosis</b> </p> <p><b>(days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to GTN diagnosis ranged across control groups from 35.7 days to 59.5 days. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to GTN diagnosis in the intervention groups was 65.5 days to 81.8 days (higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 28.72</b> (13.19 to 44.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 women<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We downgraded this evidence because the meta‐analysis included 1 study of poor methodological quality (<a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>). When this study was excluded, the results of the remaining study (<a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>; 19 women) were: MD 22.30; 95% CI −9.05 to 53.65. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of courses of chemotherapy to cure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of courses of chemotherapy required to cure subsequent GTN was 1.4 courses (10 women). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of courses of chemotherapy required to cure subsequent GTN was 2.5 courses (4 women). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.10</b> </p> <p>(0.52 to 1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 women<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This analysis only included 1 study, and we considered to be of a poor methodological quality (<a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; HM: hydatidiform mole; NNTB: number needed to treat for an additional beneficial outcome; RR: risk ratio; MD: mean difference; GTN: gestational trophoblastic neoplasia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk for the mixed‐risk population was calculated by using the weighted mean risk across the control group for this outcome. The assumed risk for the high‐risk population was based on the control group of <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>, which was the only study to evaluate a high‐risk population only. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD007289-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD007289-sec-0030"></div> <section id="CD007289-sec-0031"> <h3 class="title" id="CD007289-sec-0031">Description of the condition</h3> <p>Gestational trophoblastic disease (GTD) is a spectrum of disease characterised by an autonomous overgrowth of foetal chorionic tissue or trophoblast. Hydatidiform mole (HM) is the most common and benign form of the disease. The prevalence of HM is highest in Asia, with rates ranging from 1 to 2 per 1000 pregnancies in Japan and China (<a href="./references#CD007289-bbs2-0051" title="PalmerJR . Advances in the epidemiology of gestational trophoblastic disease. Journal of Reproductive Medicine1994;39(3):155‐62. ">Palmer 1994</a>; <a href="./references#CD007289-bbs2-0062" title="SongH , WuP . Hydatidiform mole in China: a preliminary survey of incidence of more than three million women. Bulletin of the World Health Organization1987;65(4):507‐11. ">Song 1987</a>; <a href="./references#CD007289-bbs2-0064" title="TakeuchiS . Incidence of gestational trophoblastic disease by regional registration in Japan. Human Reproduction (Oxford, England)1987;2(8):729‐34. ">Takeuchi 1987</a>), to 12 per 1000 pregnancies in Indonesia, India and Turkey (<a href="./references#CD007289-bbs2-0012" title="AzizMF , KamponoN , MoegniEM . Epidemiology of gestational trophoblastic neoplasm at the Dr.Cipto Mandunkusumo Hospital, Jakarta, Indonesia. Advances in Experimental Medicine and Biology1984;176:165‐75. ">Aziz 1984</a>; <a href="./references#CD007289-bbs2-0039" title="GülT , YilmazturkA . A review of trophoblastic diseases at the Medical School of Dicle University. European Journal of Obstetrics, Gynaecology and Reproductive Biology1997;74(1):37‐40. ">Gül 1997</a>; <a href="./references#CD007289-bbs2-0063" title="SteigradSJ . Epidemiology of gestational trophoblastic diseases. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2003;17(6):837‐47. ">Steigrad 2003</a>). In North America and Europe the incidence is reported to be lower, at 0.5 to 1 per 1000 pregnancies (<a href="./references#CD007289-bbs2-0048" title="LeeC , SmithHO , KimSJ . Chapter 3: epidemiology. In: HancockBW , NewlandsES , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Diseases. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:49‐96. www.isstd.org/isstd/chapter03.html (accessed 21 August 2012). ">Lee 2009</a>; <a href="./references#CD007289-bbs2-0063" title="SteigradSJ . Epidemiology of gestational trophoblastic diseases. Best Practice &amp; Research. Clinical Obstetrics &amp; Gynaecology2003;17(6):837‐47. ">Steigrad 2003</a>). The incidence has been reported to vary with race (<a href="./references#CD007289-bbs2-0066" title="ThamB , EverardJ , TidyJ , DrewD , HancockB . Gestational trophoblastic disease in the Asian population of Northern England and North Wales. British Journal of Obstetrics and Gynaecology2003;110(6):555‐9. ">Tham 2003</a>), maternal age (<a href="./references#CD007289-bbs2-0052" title="ParazziniF , Vecchia LL. PampollonaS . Parental age and risk of complete and partial hydatidiform mole. British Journal of Obstetrics and Gynaecology1986;93(6):582‐5. ">Parazzini 1986</a>), parity (<a href="./references#CD007289-bbs2-0014" title="BagshaweKD , DentJ , WebbJ . Hydatidiform mole in England and Wales 1973‐1983. Lancet1986;328(8508):673‐7. ">Bagshawe 1986</a>), and diet (<a href="./references#CD007289-bbs2-0017" title="BerkowitzRS , GoldsteinDP , BernsteinMR . Natural history of partial molar pregnancy. Obstetrics and Gynecology1985;66(5):677‐81. ">Berkowitz 1985</a>; <a href="./references#CD007289-bbs2-0023" title="CoullinP , DiattaAL , BoufettalH , FeingoldJ , LeguernE , CandelierJJ . The involvement of the trans‐generational effect in the high incidence of the hydatidiform mole in Africa. Placenta2015;36(1):48‐51. ">Coullin 2015</a>; <a href="./references#CD007289-bbs2-0053" title="ParazziniF , LaVecchiaC , MangiliG , CaminitiC , NegriE , CecchettiG , et al. Dietary factors and risk of trophoblastic disease. American Journal of Obstetrics and Gynecology1988;158(1):93‐9. ">Parazzini 1988</a>). Variations in prevalence may be because of differences in reporting between hospital‐based and population‐based data or in the availability of central pathology review (<a href="./references#CD007289-bbs2-0060" title="SecklMJ , SebireNJ , BerkowitzRS . Gestational trophoblastic disease. Lancet2010;376:717‐29. ">Seckl 2010</a>; <a href="./references#CD007289-bbs2-0061" title="SmithHO . Gestational trophoblastic disease epidemiology and trends. Clinical Obstetrics and Gynecology2003;46(3):541‐56. ">Smith 2003</a>). </p> <p>HMs are categorised as partial (PM) or complete moles (CM) based on their gross morphology, histopathology and karyotype. CMs usually occur when a duplicated haploid sperm fertilises an anucleate or 'empty' ovum; the ensuing diploid product (usually 46 XX) is therefore paternally derived (<a href="./references#CD007289-bbs2-0030" title="FisherR . Chapter 2: genetics. In: HancockBW , SecklM , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:6‐48. ">Fisher 2009</a>). PMs are usually triploid (69XXX, 69XXY or 69XYY), with two sets of paternal haploid genes and one set of maternal haploid genes, and occur when two sperm fertilise one ovum (<a href="./references#CD007289-bbs2-0030" title="FisherR . Chapter 2: genetics. In: HancockBW , SecklM , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:6‐48. ">Fisher 2009</a>). With CMs there is no evidence of foetal tissue; however, with PM an embryo or foetus frequently dies in early pregnancy and foetal tissue and blood cells may be identified in 20% and 50% of PM specimens, respectively (<a href="./references#CD007289-bbs2-0058" title="SebireNJ , LindsayI , ParadinasF . Chapter 4: pathology. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:97‐147. ">Sebire 2009</a>). </p> <p>HMs usually present with vaginal bleeding. Associated features (including excessive uterine enlargement, theca lutein ovarian cysts, hyperemesis, pre‐eclampsia and hyperthyroidism) are more common in CMs; however, they occur less frequently as the routine use of ultrasound has led to earlier diagnosis (<a href="./references#CD007289-bbs2-0060" title="SecklMJ , SebireNJ , BerkowitzRS . Gestational trophoblastic disease. Lancet2010;376:717‐29. ">Seckl 2010</a>). The management of PMs and CMs is similar (<a href="./references#CD007289-bbs2-0020" title="BerkowitzRS , GoldsteinDP . Chapter 9: presentation and management of molar pregnancy. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Disease, 2009:249‐76. ">Berkowitz 2009a</a>; <a href="./references#CD007289-bbs2-0021" title="BerkowitzRS , GoldsteinDP . Current management of gestational trophoblastic diseases. Gynecologic Oncology2009;112(3):654‐62. ">Berkowitz 2009b</a>). For women who want to preserve their fertility, an evacuation of the retained products of conception (ERPC) is performed, ideally by suction curettage, to remove all trophoblastic tissue completely (<a href="./references#CD007289-bbs2-0060" title="SecklMJ , SebireNJ , BerkowitzRS . Gestational trophoblastic disease. Lancet2010;376:717‐29. ">Seckl 2010</a>). After suction curettage, around 85% of CMs and more than 98% of PMs will resolve without the need for further treatment (<a href="./references#CD007289-bbs2-0050" title="NganHY , KohornEI , ColeLA , KurmanRJ , KimSJ , LurainJR , et al. Trophoblastic disease. International Journal of Gynaecology and Obstetrics2012;119 Suppl 2:S130–6.. ">Ngan 2012</a>). Most women are cured in this way; however, in some women HM persists and becomes malignant (gestational trophoblastic neoplasia (GTN)), requiring treatment with chemotherapy. In Japan, second ERPCs are performed routinely for HMs within one week of the initial ERPC, to ensure that there is no residual molar tissue in the uterus (<a href="./references#CD007289-bbs2-0057" title="SasakiS , SasakiY . Chapter 15: clinical management of trophoblastic diseases in Japan. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:398‐406. ">Sasaki 2009</a>). Second ERPCs may reduce the risk of GTN; however, to our knowledge, there is currently insufficient evidence to support this routine practice. Hysterectomy may reduce the risk of GTN by up to 10% (<a href="./references#CD007289-bbs2-0016" title="BaharAM , ElAshnehMS , SenthilsclvanA . Hydatidiform mole in the elderly: hysterectomy or evacuation?. International Journal of Gynaecology and Obstetrics1989;29(3):233‐8. ">Bahar 1989</a>; <a href="./references#CD007289-bbs2-0024" title="CurrySL , HammondCB , TyreyL , CreasmanWT , ParkerRT . Hydatidiform mole: diagnosis, management, and long‐term follow up of 347 patients. Obstetrics and Gynecology1975;45:1‐8. ">Curry 1975</a>) and is an option for women who do not wish to retain their fertility or who experience life‐threatening bleeding at the time of evacuation; however, it does not avoid the need for subsequent monitoring or chemotherapy (<a href="./references#CD007289-bbs2-0067" title="TidyJ . Chapter 18: the role of surgery in the management of gestational trophoblastic disease. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:430‐46. ">Tidy 2009</a>). </p> <p>Transformation to GTN is considered to have occurred when trophoblastic activity remains following evacuation, as shown by a plateau or rise in serial β‐human chorionic gonadotrophin (hCG) levels, raised hCG levels six months after evacuation or if the histopathological examination indicates choriocarcinoma (<a href="./references#CD007289-bbs2-0047" title="KohornEI . Chapter 7: the FIGO 2000 staging and risk factor scoring system for gestational trophoblastic neoplasia: a critical analysis. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Neoplasia. 3rd Edition. London: International Society for the Study of Trophoblastic Disease, 2009:205‐15. ">Kohorn 2009</a>). However, the presence of raised but falling hCG levels six months after evacuation of a molar pregnancy is no longer an absolute indication for chemotherapy: it appears to be safe to continue with active monitoring without detrimental effect (<a href="./references#CD007289-bbs2-0065" title="TaylorF , ShortD , HarveyR , WinterMC , TidyJ , HancockBW , et al. Late spontaneous resolution of persistent molar pregnancy. BJOG2016;123(7):1175–81. ">Taylor 2016</a>). The risk of developing GTN is reported to be 16% to 20% in women with CM (<a href="./references#CD007289-bbs2-0019" title="BerkowitzRS , GoldsteinDP . Gestational trophoblastic disease. Cancer1995;76(10 Suppl):2079‐85. ">Berkowitz 1995</a>; <a href="./references#CD007289-bbs2-0024" title="CurrySL , HammondCB , TyreyL , CreasmanWT , ParkerRT . Hydatidiform mole: diagnosis, management, and long‐term follow up of 347 patients. Obstetrics and Gynecology1975;45:1‐8. ">Curry 1975</a>; <a href="./references#CD007289-bbs2-0028" title="FelembanAA , BakriYN , AlkharifHA , AltuwaijriSM , ShalhoubJ , BerkowitzRS . Complete molar pregnancy clinical trends at King Fahad Hospital, Riyadh, Kingdom of Saudi Arabia. Journal of Reproductive Medicine1998;43(1):11‐3. ">Felemban 1998</a>; <a href="./references#CD007289-bbs2-0059" title="SecklMJ . Chapter 10: presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours/neoplasia (GTT/GTN) in the United Kingdom. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:277‐98. ">Seckl 2009</a>); and 0.5% to 1% in women with PM (<a href="./references#CD007289-bbs2-0015" title="BagshaweKD , LawlerSD , ParadinasFJ , DentJ . Gestational trophoblastic tumours following initial diagnosis of partial hydatidiform mole. Lancet1990;335:1074‐6. ">Bagshawe 1990</a>; <a href="./references#CD007289-bbs2-0059" title="SecklMJ . Chapter 10: presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours/neoplasia (GTT/GTN) in the United Kingdom. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:277‐98. ">Seckl 2009</a>). In the UK, this translates to a GTN transformation rate of approximately 8% of all molar pregnancies (<a href="./references#CD007289-bbs2-0059" title="SecklMJ . Chapter 10: presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours/neoplasia (GTT/GTN) in the United Kingdom. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:277‐98. ">Seckl 2009</a>). Thresholds for treating persistent GTD differ by region with, for example, more than twice as many women in the USA (20%) receiving chemotherapy for persistent GTD than in the UK (<a href="./references#CD007289-bbs2-0040" title="HancockBW . Chapter 19: difference in management and treatment: a critical appraisal. In: HancockBW , SecklMJ , Berkowitz , ColeLA editor(s). IGestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:447‐59. ">Hancock 2009</a>). </p> <p>HMs may be categorised as being at a low or high risk of malignant transformation based on criteria first introduced by <a href="./references#CD007289-bbs2-0013" title="BagshaweKD . Risk and prognostic factors in trophoblastic neoplasia. Cancer1976;38(3):1373‐85. ">Bagshawe 1976</a> (<a href="#CD007289-tbl-0002">Table 1</a>; <a href="./references#CD007289-bbs2-0018" title="BerkowitzRS , GoldsteinDP , DubeshterB , BernsteinM . Management of complete molar pregnancy. Journal of Reproductive Medicine1987;32(9):634‐9. ">Berkowitz 1987</a>). Women with high‐risk HMs have more than one of the following characteristics: an initial serum β‐hCG more than 100,000 mIU/mL; uterine size larger than gestational age; theca lutein cysts more than 6 cm in diameter; maternal age over 40 years; and other associated medical and epidemiological factors, including previous GTD, hyperthyroidism and trophoblastic embolisation (<a href="./references#CD007289-bbs2-0019" title="BerkowitzRS , GoldsteinDP . Gestational trophoblastic disease. Cancer1995;76(10 Suppl):2079‐85. ">Berkowitz 1995</a>). Approximately 30% to 50% of high‐risk HMs will progress to GTN (<a href="./references#CD007289-bbs2-0036" title="GoldsteinDP , BerkowitzRS , BernsteinMR . Management of molar pregnancy. Journal of Reproductive Medicine1981;26(4):208‐12. ">Goldstein 1981</a>; <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>; <a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a>). </p> <div class="table" id="CD007289-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk scoring system for the prediction of GTN in women with molar pregnancy*</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Prognostic factor</p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>U/S diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Partial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Complete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uterine size for GA (months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not more than 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>hCG level (mIU/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 50,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50,000 to &lt; 100,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100,000 to &lt; 1,000,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1,000,000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diameter of theca lutein cysts (cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6 to &lt; 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient age (years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medical complications**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>*From <a href="./references#CD007289-bbs2-0018" title="BerkowitzRS , GoldsteinDP , DubeshterB , BernsteinM . Management of complete molar pregnancy. Journal of Reproductive Medicine1987;32(9):634‐9. ">Berkowitz 1987</a> </p> <p>Low risk is defined as a score of &lt; 4; high risk is defined as a score ≥ 4</p> <p>U/S: ultrasound; GA: gestational age, hCG: β‐human chorionic gonadotrophin.</p> <p>** hyperemesis, hyperthyroidism, pre‐eclampsia, trophoblastic embolisation, disseminated intravascular coagulation. </p> </div> </div> <p>GTN, which may also follow a 'normal' pregnancy, an ectopic pregnancy or a miscarriage, is classified as low or high risk using a modified World Health Organization (WHO) scoring system adapted by the International Federation of Gynecology and Obstetrics (<a href="./references#CD007289-bbs2-0029" title="FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics2009;105(1):3‐4. ">FIGO 2009</a>). Low‐risk GTN accounts for 95% of cases in the UK and has a cure rate of almost 100% (<a href="./references#CD007289-bbs2-0060" title="SecklMJ , SebireNJ , BerkowitzRS . Gestational trophoblastic disease. Lancet2010;376:717‐29. ">Seckl 2010</a>). High‐risk GTN has a cure rate of between 80% and 90%; these lesions require combination chemotherapy regimens and frequently develop drug resistance (<a href="./references#CD007289-bbs2-0038" title="GoldsteinDP , BerkowitzRS . Current management of gestational trophoblastic neoplasia. Hematology and Oncology Clinics of North America2012;26(1):111‐31. ">Goldstein 2012</a>). </p> </section> <section id="CD007289-sec-0032"> <h3 class="title" id="CD007289-sec-0032">Description of the intervention</h3> <p>Methotrexate was first reported to be active against trophoblastic tissue in the mid‐1950s (<a href="./references#CD007289-bbs2-0041" title="HertzR , LiMC , SpencerDB . Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.)1956;93(2):361‐6. ">Hertz 1956</a>). Since then, GTN has been shown to be a highly chemosensitive disease, with various chemotherapeutic agents achieving good rates of cure. All women with 'low‐risk' GTN and approximately 80% to 90% of women with 'high‐risk' GTN will be cured following treatment with one or more chemotherapy regimens (<a href="./references#CD007289-bbs2-0060" title="SecklMJ , SebireNJ , BerkowitzRS . Gestational trophoblastic disease. Lancet2010;376:717‐29. ">Seckl 2010</a>; <a href="./references#CD007289-bbs2-0038" title="GoldsteinDP , BerkowitzRS . Current management of gestational trophoblastic neoplasia. Hematology and Oncology Clinics of North America2012;26(1):111‐31. ">Goldstein 2012</a>). Since chemotherapy drugs are associated with various toxic effects, most commonly myelotoxicity, gastrointestinal toxicity, stomatitis and alopecia, the chemotherapeutic aim when treating GTN is to provide the most effective treatment with the least toxicity. Methotrexate and dactinomycin are considered to be relatively safe agents that are commonly administered as first‐line chemotherapy for GTN, alone or in combination with other agents (<a href="./references#CD007289-bbs2-0010" title="LawrieTA , AlazzamM , TidyJ , HancockBW , OsborneR . First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD007102.pub4] ">Alazzam 2012</a>). They have not been shown to be associated with adverse reproductive outcomes, ovarian failure or second tumours (<a href="./references#CD007289-bbs2-0037" title="GoldsteinDP , BerkowitzRS . Prophylactic chemotherapy of complete molar pregnancy. Seminars in Oncology1995;22(2):157‐60. ">Goldstein 1995</a>). </p> <p>The use of prophylactic chemotherapy (P‐Chem) in women with molar pregnancy was first described in 1966 (<a href="./references#CD007289-bbs2-0049" title="LewisJL , GoreH , HertigAT , GossDA . Treatment of trophoblastic neoplasms. With rationale for the use of adjunctive chemotherapy at the time of indicated operation. American Journal of Obstetrics and Gynecology1966;96(5):710‐22. ">Lewis 1966</a>). Since then, studies of dactinomycin and methotrexate administered before, during or after evacuation of a molar pregnancy have reported encouraging results (see <a href="#CD007289-tbl-0003">Table 2</a>). Several studies have found a significant reduction in GTN for high‐risk HMs only (<a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>; <a href="./references#CD007289-bbs2-0027" title="FasoliM , RattiF , FrancheschiS , LaVecchiaC , PecorelliS , MangioniC . Management of gestational trophoblastic disease: results of a cooperative study. Obstetrics and Gynecology1982;60(2):205‐9. ">Fasoli 1982</a>; <a href="./references#CD007289-bbs2-0054" title="ParkTK , KimSN , LeeSK . Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy. Yonsei Medical Journal1996;37(6):412‐9. ">Park 1996</a>). Various dosing schedules have been described including five‐day dactinomycin (<a href="./references#CD007289-bbs2-0035" title="GoldsteinDP . Prevention of gestational trophoblastic disease by use of actinomycin D in molar pregnancies. Obstetrics and Gynecology1974;43(4):475‐9. ">Goldstein 1974</a>; <a href="./references#CD007289-bbs2-0036" title="GoldsteinDP , BerkowitzRS , BernsteinMR . Management of molar pregnancy. Journal of Reproductive Medicine1981;26(4):208‐12. ">Goldstein 1981</a>; <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>; <a href="./references#CD007289-bbs2-0054" title="ParkTK , KimSN , LeeSK . Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy. Yonsei Medical Journal1996;37(6):412‐9. ">Park 1996</a>), eight‐day methotrexate‐folinic acid (<a href="./references#CD007289-bbs2-0034" title="GoldsteinDP . Prophylactic chemotherapy of patients with molar pregnancy. Obstetrics and Gynecology1971;38(6):817‐22. ">Goldstein 1971</a>; <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>; <a href="./references#CD007289-bbs2-0054" title="ParkTK , KimSN , LeeSK . Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy. Yonsei Medical Journal1996;37(6):412‐9. ">Park 1996</a>) and single‐dose dactinomycin (<a href="./references#CD007289-bbs2-0007" title="UbertiEMH , DiestelMCF , GuimarãesFE , DeNapoliG , SchmidH . Single‐dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high‐risk hydatidiform mole. Gynecologic Oncology2006;102:325‐32. [DOI: 10.1016/j.ygyno.2005.12.036] ">Uberti 2006</a>; <a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a>). </p> <div class="table" id="CD007289-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparative studies of P‐Chem for hydatidiform mole</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Design</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> <p>(P‐Chem)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> <p>(control/no P‐Chem)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of GTN (P‐Chem)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of GTN (control)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comments</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0046" title="KogaK , MaedaK . Prophylactic chemotherapy with Amethopterin for prevention of choriocarcinoma following removal of hydatidiform mole. American Journal of Obstetrics and Gynecology1968;100(2):270‐5. ">Koga 1968</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 women (HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 women (HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methotrexate 10 mg/day PO × 7 days given within 3 weeks of ERPC.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/107 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/42 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No choriocarcinoma observed in the P‐Chem group vs 3/42 in the control group. Toxic side effects occurred in 84/107 women, including stomatitis (34/107) and myelosuppression (22/107). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0034" title="GoldsteinDP . Prophylactic chemotherapy of patients with molar pregnancy. Obstetrics and Gynecology1971;38(6):817‐22. ">Goldstein 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 intervention arms: methotrexate 0.3 mg/kg/day × 5 days (20 women); or dactinomycin 9 to 12 μg/kg/day × 5 days (53 women); ERPC on day 3. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/73</p> <p>(8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/116 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No metastatic disease observed in the P‐Chem groups. P‐Chem well tolerated with minor side effects. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0035" title="GoldsteinDP . Prevention of gestational trophoblastic disease by use of actinomycin D in molar pregnancies. Obstetrics and Gynecology1974;43(4):475‐9. ">Goldstein 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 women (HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 women (HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dactinomycin 12 μg/kg/day × 5 days. ERPC on day 3.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/100</p> <p>(2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/100</p> <p>(16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No metastatic disease observed in the P‐Chem group vs 4/100 in the control group (4%). Reversible alopecia occurred in 32% of the P‐Chem group. No serious toxic reactions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0036" title="GoldsteinDP , BerkowitzRS , BernsteinMR . Management of molar pregnancy. Journal of Reproductive Medicine1981;26(4):208‐12. ">Goldstein 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>858 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dactinomycin 12 μg/kg/day × 5 days. ERPC on day 3.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/247</p> <p>(4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160/858 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No metastatic disease observed in the P‐Chem group vs 34/858 (4%) in the control group. This report includes data from <a href="./references#CD007289-bbs2-0035" title="GoldsteinDP . Prevention of gestational trophoblastic disease by use of actinomycin D in molar pregnancies. Obstetrics and Gynecology1974;43(4):475‐9. ">Goldstein 1974</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0027" title="FasoliM , RattiF , FrancheschiS , LaVecchiaC , PecorelliS , MangioniC . Management of gestational trophoblastic disease: results of a cooperative study. Obstetrics and Gynecology1982;60(2):205‐9. ">Fasoli 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 women (92% CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methotrexate 10 mg/day PO × 5 days every 3 weeks for 3 cycles.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/104</p> <p>(3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/250</p> <p>(9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly fewer high‐risk women in the P‐Chem group (1/47) vs the control group (18/126) developed GTN (2% vs 14%; P &lt; 0.05). 2 women had severe myelosuppression and 1 had severe alopecia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT (?)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methotrexate 10 mg/day (IM or PO) for 7 days, within 3 weeks of evacuation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/293</p> <p>(7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/127</p> <p>(18%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were 5 cases of metastatic disease in each group (1.7% vs 3.9%, respectively)</p> <p>27.3% of the P‐Chem group experienced drug‐related side effects including stomatitis (10.3%), nausea/vomiting (6.8%) and leukopenia (4.4%). However none were reported to be severe. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/71 women (CM; 18/31 low‐risk and 21/40 high‐risk women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methotrexate 1.0 mg/kg/day IM (days 1, 3, 5, 7) and citrovorum factor rescue 0.1 mg/kg/day IM (days 2, 4, 6, 8). ERPC on day 3. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/39 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/32 (31%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly fewer high‐risk women in the P‐Chem group (14%) vs the control group (47%) developed GTN. There was no significant difference in the GTN rates of low‐risk women between groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0054" title="ParkTK , KimSN , LeeSK . Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy. Yonsei Medical Journal1996;37(6):412‐9. ">Park 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 women (14 low‐risk, 21 medium‐risk and 17 high‐risk HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 women</p> <p>(38 low‐risk, 25 medium‐risk and 25 high‐risk HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methotrexate 1 mg/kg (days 1, 3, 5, 7) and citrovorum factor (0.1 mg/kg (days 2, 4, 6, 8); or dactinomycin 12 μg/kg/day × 5 days started at the time of ERPC. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/52</p> <p>(15.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/88 (31.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly fewer high‐risk women in the P‐Chem group (7/17) vs the control group (22/25) developed GTN (41% vs 88%; P &lt; 0.01). There was no significant difference in the GTN rates in low‐ and medium‐risk women between groups. The time to achieve normal hCG levels was shorter in high‐risk women in the P‐Chem group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 women (high‐risk CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 women (high risk CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dactinomycin 10 µg/kg for 5 days, within 1 week after ERPC and histology.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/29</p> <p>(15.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/30</p> <p>(50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild, reversible side effects reported including stomatitis (10%), nausea/vomiting (10%), oral ulcers (3.3%) and hair loss (13.3%) ‒ all grade 1 except for 2 women with grade 2 patchy alopecia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0007" title="UbertiEMH , DiestelMCF , GuimarãesFE , DeNapoliG , SchmidH . Single‐dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high‐risk hydatidiform mole. Gynecologic Oncology2006;102:325‐32. [DOI: 10.1016/j.ygyno.2005.12.036] ">Uberti 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 adolescents</p> <p>(high‐risk CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 adolescents</p> <p>(high‐risk CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dactinomycin 1.25 mg/m² IV given 1 hour before ERPC.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/29</p> <p>(6.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/31</p> <p>(29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean risk scores and hCG levels were significantly higher and gestational age was significantly lower in the P‐Chem group than the control group. Mild and transient side effects included hepatotoxicity (10%) and mild alopecia (6.8%). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 women</p> <p>(high risk, &gt; 90% CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 women</p> <p>(high risk, &gt; 90% CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dactinomycin 1.25 mg/m² IV given 1 hour before ERPC.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/163 (18.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/102 (34.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild and transient side effects including nausea (8%), raised liver enzymes (3.7%), stomatitis (3.1%), rash (2.4%) diarrhoea (2.4%), alopecia (1.2%) and neutropenia (0.6%) were seen in 21% of the P‐Chem group. Time to GTN diagnosis, subsequent drug resistance and the number of chemotherapy course to cure was similar in the 2 groups. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>* Three studies administered P‐Chem after ERPC including <a href="./references#CD007289-bbs2-0046" title="KogaK , MaedaK . Prophylactic chemotherapy with Amethopterin for prevention of choriocarcinoma following removal of hydatidiform mole. American Journal of Obstetrics and Gynecology1968;100(2):270‐5. ">Koga 1968</a>, <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> and <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>. </p> <p>CM; complete mole; ERPC: evacuation of retained products of conception; GTN: gestational trophoblastic neoplasia; HM: hydatidiform mole; IM: intramuscular; IV: intravenous; P‐Chem; prophylactic chemotherapy; PO: per os; RCT: randomised controlled trial. </p> </div> </div> </section> <section id="CD007289-sec-0033"> <h3 class="title" id="CD007289-sec-0033">How the intervention might work</h3> <p>As GTN is a highly chemosensitive disease, prophylaxis with chemotherapy agents that have known activity against trophoblast tumour cells may prevent progression to GTN. The use of P‐Chem has been based on an assumption that the development of GTN is pre‐determined, that metastatic GTN spreads via the bloodstream and that high serum levels of cytotoxic agents around the time of evacuation should reduce the ability of the trophoblast cells to invade or metastasise (<a href="./references#CD007289-bbs2-0037" title="GoldsteinDP , BerkowitzRS . Prophylactic chemotherapy of complete molar pregnancy. Seminars in Oncology1995;22(2):157‐60. ">Goldstein 1995</a>). </p> <p>P‐Chem may be particularly useful in women with high‐risk CMs who have poor access to health care, for whom hormonal follow‐up is not available, or where poor compliance may be an issue (<a href="./references#CD007289-bbs2-0020" title="BerkowitzRS , GoldsteinDP . Chapter 9: presentation and management of molar pregnancy. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Disease, 2009:249‐76. ">Berkowitz 2009a</a>; <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>; <a href="./references#CD007289-bbs2-0007" title="UbertiEMH , DiestelMCF , GuimarãesFE , DeNapoliG , SchmidH . Single‐dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high‐risk hydatidiform mole. Gynecologic Oncology2006;102:325‐32. [DOI: 10.1016/j.ygyno.2005.12.036] ">Uberti 2006</a>). In Latin America, loss to follow‐up may be as high as 44% in some areas; hence numerous referral centres in this region are reported to use P‐Chem (<a href="./references#CD007289-bbs2-0022" title="CharryRC . Chapter 16: presentation and management of molar pregnancy and gestational trophoblastic neoplasia in Latin America. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:407‐19. ">Charry 2009</a>). However, the use of P‐Chem may expose women to toxic side effects (<a href="./references#CD007289-bbs2-0045" title="KayeDD . Gestational trophoblastic disease following complete hydatidiform mole in Mulago Hospital, Kampala, Uganda. African Health Sciences2002;2(2):47‐51. ">Kaye 2002</a> and <a href="./references#CD007289-bbs2-0055" title="RatnamSS , TeohES , DawoodMY . Methotrexate for prophylaxis of choriocarcinoma. American Journal of Obstetrics and Gynecology1971;111(8):1021‐7. ">Ratnam 1971</a> have reported toxicity‐related deaths with methotrexate prophylaxis), may lead to inadequate follow‐up, and incompletely protects women against persistent tumour (<a href="./references#CD007289-bbs2-0037" title="GoldsteinDP , BerkowitzRS . Prophylactic chemotherapy of complete molar pregnancy. Seminars in Oncology1995;22(2):157‐60. ">Goldstein 1995</a>; <a href="./references#CD007289-bbs2-0040" title="HancockBW . Chapter 19: difference in management and treatment: a critical appraisal. In: HancockBW , SecklMJ , Berkowitz , ColeLA editor(s). IGestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:447‐59. ">Hancock 2009</a>). Furthermore, P‐Chem may favour the development of drug resistance (<a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>) and delay the time to effective treatment, thereby having adverse effects on survival. </p> </section> <section id="CD007289-sec-0034"> <h3 class="title" id="CD007289-sec-0034">Why it is important to do this review</h3> <p>P‐Chem for high‐risk HM appears to be routine clinical practice in some regions of the world (<a href="./references#CD007289-bbs2-0022" title="CharryRC . Chapter 16: presentation and management of molar pregnancy and gestational trophoblastic neoplasia in Latin America. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:407‐19. ">Charry 2009</a>). Although several studies have been reported, it remains unclear whether P‐Chem, which may be associated with substantial toxicity, will prevent malignant transformation of HM. Furthermore, if P‐Chem benefits exist, it is not clear which drug regimen might have the best effectiveness‐to‐toxicity ratio. We undertook this review in an attempt to clarify the benefits and risks associated with P‐Chem for HM. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD007289-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD007289-sec-0035"></div> <p>To evaluate the effectiveness and safety of P‐Chem for the prevention of GTN in women with molar pregnancy. </p> <p>To investigate whether any subgroup of women with HM may benefit more from P‐Chem than others. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD007289-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD007289-sec-0036"></div> <section id="CD007289-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD007289-sec-0038"> <h4 class="title">Types of studies</h4> <p>Randomised controlled trials (RCTs).</p> </section> <section id="CD007289-sec-0039"> <h4 class="title">Types of participants</h4> <section id="CD007289-sec-0040"> <h5 class="title">Inclusions</h5> <p>All women diagnosed with HM.</p> </section> <section id="CD007289-sec-0041"> <h5 class="title">Exclusions</h5> <p>Women who were diagnosed with other types of GTD such as invasive moles, choriocarcinoma and placental site trophoblastic tumour (PSTT). </p> </section> </section> <section id="CD007289-sec-0042"> <h4 class="title">Types of interventions</h4> <p>P‐Chem compared with no or other treatments (e.g. placebo or analgesic drugs).</p> </section> <section id="CD007289-sec-0043"> <h4 class="title">Types of outcome measures</h4> <section id="CD007289-sec-0044"> <h5 class="title">Primary outcomes</h5> <p> <ul id="CD007289-list-0001"> <li> <p>Incidence of GTN (invasive mole, choriocarcinoma, PSTT and epithelioid trophoblastic tumour (ETT). </p> </li> </ul> </p> </section> <section id="CD007289-sec-0045"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD007289-list-0002"> <li> <p>Drug toxicity, including myelotoxicity, gastrointestinal toxicity, stomatitis and alopecia. </p> </li> <li> <p>Overall survival (more than 5 years).</p> </li> <li> <p>Time to negative conversion of serum or urine β‐hCG.</p> </li> <li> <p>Time to GTN diagnosis.</p> </li> <li> <p>Incidence and nature of subsequent pregnancies.</p> </li> <li> <p>Quality of life (QoL).</p> </li> </ul> </p> </section> </section> </section> <section id="CD007289-sec-0046"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD007289-sec-0047"> <h4 class="title">Electronic searches</h4> <p>For the original review we searched the Cochrane Gynaecological Cancer Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 2, 2012), MEDLINE (1946 to February week 4, 2012) and Embase (1980 to 2012, week 9). For this review update we searched the Cochrane Central Register of Controlled Trials (CENTRAL, Issue 5, 2017) in the Cochrane Library (<a href="./appendices#CD007289-sec-0097">Appendix 1</a>), MEDLINE (February 2012 to June week 1, 2017) (<a href="./appendices#CD007289-sec-0098">Appendix 2</a>) and Embase (February 2012 to 2017, week 23) (<a href="./appendices#CD007289-sec-0099">Appendix 3</a>). No language restriction was applied. </p> </section> <section id="CD007289-sec-0048"> <h4 class="title">Searching other resources</h4> <p>All relevant articles were identified in PubMed; and, using the 'related articles' feature, a further search was carried out for newly published articles. The reference lists from identified published trials were handsearched for further clinical trials. Papers in all languages were sought and translated as necessary. We searched the <i>meta</i> Register of Controlled Trials (<i>m</i>RCT) and the National Research Register (NRR) archive for ongoing trials. </p> </section> </section> <section id="CD007289-sec-0049"> <h3 class="title" id="CD007289-sec-0049">Data collection and analysis</h3> <section id="CD007289-sec-0050"> <h4 class="title">Selection of studies</h4> <p>We downloaded all titles and abstracts retrieved by electronic searching to a reference management database, removed duplicates and two review authors (JF, FH) independently examined the remaining references. We excluded those studies that clearly did not meet the inclusion criteria and obtained copies of the full text of potentially relevant references. Three review authors (JF, LX, TL) independently assessed the eligibility of retrieved papers. We documented the reasons for exclusion. </p> </section> <section id="CD007289-sec-0051"> <h4 class="title">Data extraction and management</h4> <p>For included studies, three review authors (JF, HC, TL) independently extracted data on the following parameters: patient characteristics; number recruited to each arm; number excluded from analysis; type of intervention; proportion of participants who received all, part or none of the intended treatment; methods of randomisation, blinding and allocation concealment; length of follow‐up; and outcome. Review authors resolved disagreements by discussion or by appeal to a fourth review author (one of LH, FF or TW) if necessary. </p> </section> <section id="CD007289-sec-0052"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>We used Cochrane's tool for assessing risk of bias (<a href="./references#CD007289-bbs2-0043" title="HigginsJPT , GreenS (editors) . Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org. ">Higgins 2011</a>). Three review authors (JF, LX, TL) independently assessed the risk of bias within each included study based on the following six domains, with review authors' judgements presented as answers of 'yes' (low risk of bias); 'no' (high risk of bias), or 'unclear' (uncertain risk of bias). </p> <p> <ul id="CD007289-list-0003"> <li> <p>Selection bias: random sequence generation and allocation concealment.</p> </li> <li> <p>Performance bias: blinding of participants and personnel (women and treatment providers).</p> </li> <li> <p>Detection bias: blinding of outcome assessment.</p> </li> <li> <p>Attrition bias: incomplete outcome data. We considered studies to be at a high risk of bias if more than 20% of women were lost to follow‐up or reasons for loss to follow‐up differed between treatment arms. </p> </li> <li> <p>Reporting bias: selective reporting of outcomes.</p> </li> <li> <p>Other possible sources of bias.</p> </li> </ul> </p> </section> <section id="CD007289-sec-0053"> <h4 class="title">Assessment of heterogeneity</h4> <p>We used random‐effects models for all meta‐analyses (<a href="./references#CD007289-bbs2-0026" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). We assessed heterogeneity between studies by visual inspection of forest plots; by estimation of the I² statistic, which summarises the percentage heterogeneity between trials that cannot be ascribed to sampling variation; and by a formal statistical test of the significance of the heterogeneity (<a href="./references#CD007289-bbs2-0025" title="DeeksJJ , AltmanDG , BradburnMJ . Statistical methods for examining heterogeneity and combining results from several studies in meta‐analysis. In: EggerM , Davey SmithG , AltmanDG editor(s). Systematic Reviews in Health Care: Meta‐Analysis in Context. 2nd Edition. London: BMJ Publication Group, 2001. ">Deeks 2001</a>). I² less than 25% was considered as low‐level heterogeneity, 25% to 50% as a moderate level, and higher than 50% as substantial heterogeneity (<a href="./references#CD007289-bbs2-0042" title="HigginsJP , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analysis. BMJ2003;327(7414):557‐60. ">Higgins 2003</a>). If there was evidence of substantial heterogeneity, the possible reasons for this were investigated and reported. </p> </section> <section id="CD007289-sec-0054"> <h4 class="title">Data synthesis</h4> <p>Meta‐analysis was carried out using Review Manager 5 software (<a href="./references#CD007289-bbs2-0056" title="Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014. ">Review Manager 2014</a>). We used random‐effects models for all meta‐analyses (<a href="./references#CD007289-bbs2-0026" title="DerSimonianR , LairdN . Meta‐analysis in clinical trials. Controlled Clinical Trials1986;7(3):177‐88. ">DerSimonian 1986</a>). For dichotomous outcomes, we calculated risk ratios (RR) and associated 95% confidence intervals (CIs). For continuous outcomes we pooled the mean differences (MD) between the treatment arms where trials measured the outcome on the same scale. </p> </section> <section id="CD007289-sec-0055"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>We subgrouped women by the type of chemotherapy agent (i.e. methotrexate and dactinomycin). We had planned to perform other subgroup analyses, including subgroups of women at a low and high risk of GTN, and according to drug regimens; however, this was not possible since these data were not reported in the included trials. </p> </section> <section id="CD007289-sec-0056"> <h4 class="title">Sensitivity analysis</h4> <p> We performed sensitivity analysis to assess the robustness of the meta‐analyses by comparing the results using all trials and then excluding trials of lower methodological quality or those considered to be at a higher risk of bias. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD007289-sec-0057" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD007289-sec-0057"></div> <section id="CD007289-sec-0058"> <h3 class="title">Description of studies</h3> <section id="CD007289-sec-0059"> <h4 class="title">Results of the search</h4> <p>From the search, we identified and screened 161 records. After de‐duplication, and title and abstract screening, we retrieved the full text of 90 citations that we considered potentially eligible for inclusion in this review. We excluded 81 out of these 90 papers. Of the remaining nine reports, we excluded four on the basis that they were not RCTs (<a href="./references#CD007289-bbs2-0005" title="GengS , FengFZ , XiangY , WanXR , ZhouY , ZhonghuaFu , et al. Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high‐risk hydatidiform mole. Zhonghua Fu Chan Ke Za Zhi2011;46(1):24‐7. [Chinese] ">Geng 2011</a>; <a href="./references#CD007289-bbs2-0007" title="UbertiEMH , DiestelMCF , GuimarãesFE , DeNapoliG , SchmidH . Single‐dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high‐risk hydatidiform mole. Gynecologic Oncology2006;102:325‐32. [DOI: 10.1016/j.ygyno.2005.12.036] ">Uberti 2006</a>; <a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a> ‒ two papers); and two RCTs which enrolled gestational trophoblastic neoplasia (<a href="./references#CD007289-bbs2-0004" title="YarandiF , MousaviA , AbbasluF , AminimoghaddamS , NekuieS , AdabiK , HanjaniP . Five‐Day Intravascular Methotrexate Versus Biweekly Actinomycin‐D in the Treatment of Low‐Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial. International Journal of Gynecological Cancer2016;26(5):971‐6. ">Fariba 2016</a>; <a href="./references#CD007289-bbs2-0006" title="MousaviA , CheraghiF , YarandiF , GilaniMM , Shojaei . Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease. International Journal of Gynaecology and Obstetrics2012;116(1):39‐42. ">Mousavi 2012</a>). We included the remaining three studies (<a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a>; <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>; <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>). The selection‐of‐study process is represented in a PRISMA Flow Diagram (<a href="#CD007289-fig-0001">Figure 1</a>). </p> <div class="figure" id="CD007289-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD007289-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD007289-sec-0060"> <h4 class="title">Included studies</h4> <p>We included three studies with a total of 613 participants (<a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a>; <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>; <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>). Two studies used prophylactic methotrexate and one trial used prophylactic dactinomycin. The number of evaluable participants in the three studies was 550. See <a href="./references#CD007289-sec-0108" title="">Characteristics of included studies</a>. </p> <p><a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> 'randomly selected' 420 women with low‐ or high‐risk CM to receive one course of prophylactic methotrexate (10 mg daily for seven days) within three weeks of ERPC, or no prophylaxis, and evaluated subsequent rates of GTN in the two groups. </p> <p><a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> randomised 133 women with low‐ or high‐risk CM to prophylactic methotrexate or no prophylaxis. Only 71 out of 133 women completed this trial and were included in the analyses (39 in the treatment group and 32 in the untreated group). The intervention group (18 out of 31 low‐risk women and 21 out of 40 high‐risk women) received one course of methotrexate with citrovorum rescue factor (methotrexate 1.0 mg/kg/day intramuscular (IM) on days 1, 3, 5 and 7; citrovorum rescue factor 0.1 mg/kg/day IM on days 2, 4, 6 and 8); the control group received no treatment. The ERPC in the intervention group was done on the third or fourth day of P‐Chem. </p> <p><a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> randomised 60 women with high‐risk CM to dactinomycin prophylaxis (10 μg/kg body weight daily for 5 days; 30 women) or no prophylaxis (30 women) within one week after ERPC. One woman was lost to follow‐up. </p> </section> <section id="CD007289-sec-0061"> <h4 class="title">Excluded studies</h4> <p>We excluded three retrospective studies (<a href="./references#CD007289-bbs2-0005" title="GengS , FengFZ , XiangY , WanXR , ZhouY , ZhonghuaFu , et al. Analysis of prophylactic chemotherapy outcome and clinical characteristics in patients of high‐risk hydatidiform mole. Zhonghua Fu Chan Ke Za Zhi2011;46(1):24‐7. [Chinese] ">Geng 2011</a>; <a href="./references#CD007289-bbs2-0007" title="UbertiEMH , DiestelMCF , GuimarãesFE , DeNapoliG , SchmidH . Single‐dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high‐risk hydatidiform mole. Gynecologic Oncology2006;102:325‐32. [DOI: 10.1016/j.ygyno.2005.12.036] ">Uberti 2006</a>; <a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a>), and two RCTs that enrolled participants with gestational trophoblastic neoplasia (<a href="./references#CD007289-bbs2-0004" title="YarandiF , MousaviA , AbbasluF , AminimoghaddamS , NekuieS , AdabiK , HanjaniP . Five‐Day Intravascular Methotrexate Versus Biweekly Actinomycin‐D in the Treatment of Low‐Risk Gestational Trophoblastic Neoplasia: A Clinical Randomized Trial. International Journal of Gynecological Cancer2016;26(5):971‐6. ">Fariba 2016</a>; <a href="./references#CD007289-bbs2-0006" title="MousaviA , CheraghiF , YarandiF , GilaniMM , Shojaei . Comparison of pulsed actinomycin D versus 5‐day methotrexate for the treatment of low‐risk gestational trophoblastic disease. International Journal of Gynaecology and Obstetrics2012;116(1):39‐42. ">Mousavi 2012</a>); see <a href="./references#CD007289-sec-0109" title="">Characteristics of excluded studies</a>. </p> </section> </section> <section id="CD007289-sec-0062"> <h3 class="title">Risk of bias in included studies</h3> <p>We assessed the risk of bias of the three included RCTs using the Cochrane's 'Risk of bias' tool; see <a href="#CD007289-fig-0002">Figure 2</a>. Overall, we consider the older studies of <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> and <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> to be at a high risk of bias and <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> to be at a low risk of bias. Dr. Limpongsanurak provided us with additional methodological details for <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> via e‐mail. Although we attempted to contact the other authors by e‐mail for more details, we were unsuccessful as we had no contact details for the authors of <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>, and received no reply to our queries from Dr. Kashimura (<a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a>). </p> <div class="figure" id="CD007289-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD007289-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> </div> <section id="CD007289-sec-0063"> <h4 class="title">Allocation</h4> <p><a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> used lot‐drawing to randomise women and sealed opaque envelopes to conceal random group allocations; we assessed these methods to be at a low risk of bias. We assessed the randomisation and allocation methods used in <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> to be of unclear risk of bias and assessed the random sequence generation in <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> to be at a high risk of bias. In the latter report, participants were "selected at random", which suggests that participant selection in this study may not have been a truly random process. Furthermore, no randomisation ratio was described and yet the intervention and control groups were very different sizes (293 women versus 127 women). </p> </section> <section id="CD007289-sec-0064"> <h4 class="title">Blinding</h4> <p>The only trial that reported blinding was <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>. Although precise details were not reported, this trial was described as 'double‐blind' as control participants received a similar‐looking intravenous (IV) solution with analgesic drugs for five days, and neither the participant nor the attending doctor knew to which group the participant had been allocated. It is unclear whether outcome assessment was also blind. </p> </section> <section id="CD007289-sec-0065"> <h4 class="title">Incomplete outcome data</h4> <p>We assessed <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> as being at a high risk of attrition bias as 62 out of 133 women were excluded from the analyses owing to loss to follow‐up (36 women), insufficient length of follow‐up (7 women) and hysterectomy (19 women). Of the 60 women in <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>, one woman in the P‐Chem group was lost to follow‐up one month after treatment and was not included in the main analyses. <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> reported complete data sets for the main outcomes. </p> </section> <section id="CD007289-sec-0066"> <h4 class="title">Selective reporting</h4> <p>All pre‐specified outcomes were reported for <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> and <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>. <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> failed to report baseline characteristics of the two study groups that could represent reporting bias, especially since there were proportionally more women aged 40 years and over in the control group. </p> </section> <section id="CD007289-sec-0067"> <h4 class="title">Other potential sources of bias</h4> <p>In <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a>, more women in the control group were 40 years old and over (22% in control group versus 11% in P‐Chem group). The older women were more likely to progress to GTN (39% versus 12%). This may have biased the results in favour of the P‐Chem group. </p> <p><a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> included women with high‐risk CM only, whereas <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> and <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> included women with low‐ and high‐risk CM. Since <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> showed that P‐Chem was not beneficial to women with low‐risk CM, by including these women the meta‐analysis results may be biased in the direction of the control arm. </p> <p><a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> and <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> gave P‐Chem after ERPC whereas <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> started P‐Chem before the ERPC. If treatment was commenced before ERPC, this trial may have included women with PM and hydropic abortion that would otherwise have been excluded following histological diagnosis of evacuation products. It is unclear whether women with PM or hydropic abortion were present in the same numbers within the allocated groups. </p> <p><a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> and <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> were older studies that took place before rigorous RCT guidelines were in place and therefore are lacking in methodological quality. It is not possible to determine whether these were true RCTs so we have assumed that they were but considered them to be at a high risk of bias overall; therefore we have performed sensitivity analysis and downgraded the results accordingly. </p> </section> </section> <section id="CD007289-sec-0068"> <h3 class="title" id="CD007289-sec-0068">Effects of interventions</h3> <p>See: <a href="./full#CD007289-tbl-0001"><b>Summary of findings for the main comparison</b> </a> </p> <section id="CD007289-sec-0069"> <h4 class="title">Incidence of GTN</h4> <section id="CD007289-sec-0070"> <h5 class="title">Incidence of GTN (overall)</h5> <p>P‐Chem was associated with a significant reduction in the incidence of GTN compared with the control group (3 studies; 550 participants; 30 out of 361 versus 48 out of 189; RR 0.37, 95% CI 0.24 to 0.57; I² = 0%; P &lt; 0.00001; low‐quality evidence) with no significant difference between methotrexate and dactinomycin prophylaxis subgroups (<a href="./references#CD007289-fig-0003" title="">Analysis 1.1</a>). </p> <p>We performed sensitivity analysis for this outcome as two of the included studies were at a high risk of bias. When these two studies (both in the methotrexate subgroup) were excluded, only one trial remained (59 participants; 4 out of 29 versus 15 out of 30; RR 0.28, 95% CI 0.10 to 0.73; P = 0.01); therefore we consider this evidence to be of low quality. </p> </section> <section id="CD007289-sec-0071"> <h5 class="title">Incidence of GTN (high‐risk HM only)</h5> <p>When only high‐risk women were included, P‐Chem was similarly associated with a significant reduction in the incidence of GTN compared with the control group (2 studies; 99 participants; 7 out of 50 versus 24 out of 49; RR 0.29, 95% CI 0.14 to 0.60; I² = 0%; P = 0.001; low‐quality evidence) (<a href="./references#CD007289-fig-0004" title="">Analysis 1.2</a>). Sensitivity analysis gave the same results as above when the only well‐conducted trial was included (59 participants; 4 out of 29 versus 15 out of 30; RR 0.28, 95% CI 0.10 to 0.73; P = 0.01; low‐quality evidence). </p> </section> <section id="CD007289-sec-0072"> <h5 class="title">Invasive mole and choriocarcinoma</h5> <p>There were insufficient data from these trials to analyse the rates of invasive mole and choriocarcinoma in the study groups. <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> utilised a prognostic scoring system to diagnose GTN (not histology) and secondary histology was known in only three participants, two of whom underwent hysterectomy for excessive bleeding. <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> diagnosed 27 out of 45 cases of GTN histologically and 18 out of 45 by a Japanese prognostic scoring system. Four of these participants had choriocarcinoma (two in each study group) and 41 were considered to have invasive mole. <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> diagnosed most cases of GTN based on persistent or rising hCG levels, persistent or recurrent uterine haemorrhage, or clinical/histological evidence of metastases, and did not distinguish between invasive mole and choriocarcinoma. </p> </section> </section> <section id="CD007289-sec-0073"> <h4 class="title">Time to GTN diagnosis</h4> <p>Two studies reported this outcome for 33 participants who developed GTN (<a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>; <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>). The time to GTN diagnosis was significantly longer in the P‐Chem group compared with the control group (MD 28.72 days, 95% CI 13.19 to 44.24; I² = 0%; P = 0.0003; low‐quality evidence) (<a href="./references#CD007289-fig-0005" title="">Analysis 1.3</a>). When we excluded <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> from the sensitivity analysis, results for the one remaining study were similar but not significant (19 participants; MD 22.30 days, 95% CI 9.05 to 53.65; P = 0.16). </p> </section> <section id="CD007289-sec-0074"> <h4 class="title">Toxicity</h4> <p>None of the studies reported adverse effects in the control groups and we have not imputed these data. <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> (five‐day dactinomycin) only reported side effects as percentages, including stomatitis (10%), nausea or vomiting (10%), oral ulcers (3.3%) and hair loss (13.3%). All adverse effects in this study were grade 1 except for two women with patchy alopecia (grade 2). The other two studies reported the following. </p> <p> <ul id="CD007289-list-0004"> <li> <p><a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> (239 women): stomatitis (10.3%), nausea or vomiting (6.8%) and leukopenia (4.4%). </p> </li> <li> <p><a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> (39 women): epithelial (5.1%), hepatic (7.7%), haematological (7.7%) and neuromuscular (2.6%) toxicity. </p> </li> </ul> </p> <p>In these two studies, grades of toxicity were not reported. Both reports state that there were no severe complications or drug‐related deaths. </p> </section> <section id="CD007289-sec-0075"> <h4 class="title">Courses of chemotherapy</h4> <p>Only one poor‐quality study reported this outcome. Women in the methotrexate prophylaxis group needed more subsequent chemotherapy courses for GTN treatment than the control group (14 women; MD 1.10, 95% CI 0.52 to 1.68; P = 0.0002; very low quality evidence). </p> </section> <section id="CD007289-sec-0076"> <h4 class="title">Survival</h4> <p>There were no deaths during the follow‐up periods in <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> and <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>; however, <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> reported three deaths from metastatic disease that occurred two to 12 years after ERPC, including two women in the P‐Chem group and one in the control group. </p> </section> <section id="CD007289-sec-0077"> <h4 class="title">Subsequent pregnancies</h4> <p><a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> did not report subsequent pregnancy rates. Women in <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> were given contraception for one year after ERPC and subsequent pregnancy rates were assessed. Out of 51 women who attempted to become pregnant, 40 had 44 pregnancies including 24 out of 29 in the P‐Chem group and 16 out of 22 in the control group. The rates of full‐term pregnancies were reported as being similar in the two groups (25 out of 27 (93%) in the P‐Chem group versus 16 out of 17 (94%) in the control group). </p> <p><a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> obtained these data for 101 out of 420 participants only (24%): 74 out of 112 (67%) subsequent pregnancies were normal full‐term pregnancies in the P‐Chem group compared with 19 out of 31 (61%) in the control group. The induced abortion rate was 22% of pregnancies in the P‐Chem group and 13% in the control group. </p> <p>It was not possible to perform a meta‐analysis of these very limited data.</p> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD007289-sec-0078" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD007289-sec-0078"></div> <section id="CD007289-sec-0079"> <h3 class="title" id="CD007289-sec-0079">Summary of main results</h3> <p>In a limited meta‐analysis of three studies that included low‐ and high‐risk molar pregnancies, P‐Chem reduced the incidence of subsequent GTN by approximately two‐thirds overall. On sensitivity analysis, where the only satisfactory study (high‐risk women only) contributed data, the results showed a similar effect but with a wider CI; (see <a href="./full#CD007289-tbl-0001">summary of findings Table for the main comparison</a>). The interpretation of these results was influenced by the poor methodological quality of the two older included studies, and the small number of participants in the only other study. We therefore consider this evidence to be of low quality. </p> <p>The diagnosis of GTN occurred approximately one month later in the P‐Chem group compared with the control group in the meta‐analysis of two studies that reported this outcome. The P‐Chem group needed approximately one extra course of chemotherapy than the control group to achieve a cure in the participants whose disease progressed to GTN. We consider this evidence to be of very low quality for similar reasons to those given above. </p> <p>Data on toxicity were insufficient for meta‐analysis; however, it was reported that no participants in any of the studies experienced severe drug‐related complications or deaths. </p> </section> <section id="CD007289-sec-0080"> <h3 class="title" id="CD007289-sec-0080">Overall completeness and applicability of evidence</h3> <p>We consider this evidence to be incomplete and not widely applicable.</p> <section id="CD007289-sec-0081"> <h4 class="title">Incidence of GTN</h4> <p>This limited evidence in favour of P‐Chem may apply to women with high‐risk CM only. <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> found that P‐Chem did not benefit women with low‐risk HM and some non‐randomised studies have drawn similar conclusions (<a href="./references#CD007289-bbs2-0027" title="FasoliM , RattiF , FrancheschiS , LaVecchiaC , PecorelliS , MangioniC . Management of gestational trophoblastic disease: results of a cooperative study. Obstetrics and Gynecology1982;60(2):205‐9. ">Fasoli 1982</a>; <a href="./references#CD007289-bbs2-0054" title="ParkTK , KimSN , LeeSK . Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy. Yonsei Medical Journal1996;37(6):412‐9. ">Park 1996</a>). This is probably why the more recent studies have excluded low‐risk women (e.g. <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>; <a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a>). Furthermore, the incidence of GTN in the high‐risk control groups of included studies was high, at 47% and 50% for <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> and <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>, respectively. This may reflect regional differences in the rates of CM transformation or the selection/diagnostic criteria applied, and needs further clarification. </p> <p>Only two chemotherapeutic agents, namely methotrexate and actinomycin D, were investigated. None of the included studies evaluated the less toxic single‐dose regimens of these agents that have been shown to be useful to treat low‐risk GTN (<a href="./references#CD007289-bbs2-0010" title="LawrieTA , AlazzamM , TidyJ , HancockBW , OsborneR . First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD007102.pub4] ">Alazzam 2012</a>). One RCT of single‐dose dactinomycin for P‐Chem was proposed by <a href="./references#CD007289-bbs2-0037" title="GoldsteinDP , BerkowitzRS . Prophylactic chemotherapy of complete molar pregnancy. Seminars in Oncology1995;22(2):157‐60. ">Goldstein 1995</a>, but has never been conducted. <a href="./references#CD007289-bbs2-0007" title="UbertiEMH , DiestelMCF , GuimarãesFE , DeNapoliG , SchmidH . Single‐dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high‐risk hydatidiform mole. Gynecologic Oncology2006;102:325‐32. [DOI: 10.1016/j.ygyno.2005.12.036] ">Uberti 2006</a> and <a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a> report the results of two retrospective studies of single‐dose dactinomycin administered before evacuation of high‐risk molar pregnancies, showing a reduction in post‐molar GTN of 76% and 46%, respectively, with minimal adverse effects. Since this low‐dose dactinomycin regimen appears to be in practice (personal communication with Dr Uberti) it should be evaluated in an RCT. </p> </section> <section id="CD007289-sec-0082"> <h4 class="title">Toxicity</h4> <p>Toxicity was not rigorously reported in the included studies and meta‐analyses of these data were not possible. When used to treat low‐risk GTN, five‐day dactinomycin and five‐ and eight‐day methotrexate regimens have been associated with severe adverse effects including myelosuppression, hepatotoxicity and alopecia (dactinomycin); hence there is a move towards less toxic chemotherapy regimens for the treatment of low‐risk GTN (<a href="./references#CD007289-bbs2-0010" title="LawrieTA , AlazzamM , TidyJ , HancockBW , OsborneR . First‐line chemotherapy in low‐risk gestational trophoblastic neoplasia. Cochrane Database of Systematic Reviews2016, Issue 6. [DOI: 10.1002/14651858.CD007102.pub4] ">Alazzam 2012</a>). For this reason, the more toxic five‐ and eight‐day regimens that have historically been used in studies of P‐Chem (<a href="#CD007289-tbl-0003">Table 2</a>) are unlikely to be favoured as prophylaxis for HM. </p> </section> <section id="CD007289-sec-0083"> <h4 class="title">Survival</h4> <p>Only one study reported long‐term follow‐up (<a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a>), with three deaths occurring from metastatic disease between 2 and 12 years after ERPC (2 in the P‐Chem group and 1 in the control group); neither <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> nor <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> assessed the impact of P‐Chem on long‐term overall survival, hence the evidence for this outcome is incomplete. Longer follow‐up of participants is needed in any future studies of P‐Chem interventions for HM. </p> </section> <section id="CD007289-sec-0084"> <h4 class="title">Subsequent pregnancy and quality of life (QoL)</h4> <p>Although subsequent pregnancies were reported by <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> and <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>, these data were incomplete (owing to high attrition) and it was not possible to draw any conclusions. <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> reported that 78.4% of their participants experienced at least one pregnancy after one year of contraception during the follow‐up period and the frequency of full‐term delivery was 92.6% and 94.1%, for the treatment and control groups respectively. In <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a>, comparable rates of secondary infertility and a similar time to first menstruation after ERPC were reported in the P‐Chem and control groups. Neither <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> nor <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> assessed the impact of P‐Chem on long‐term ovarian function or QoL. However, these chemotherapy agents have been used extensively to treat GTN over several decades and have not been shown to adversely affect reproductive outcomes or ovarian function, or to be associated with second tumours (<a href="./references#CD007289-bbs2-0032" title="GarnerEI , LipsonE , BernsteinMR . Subsequent pregnancy experience in patients with molar pregnancy and gestational trophoblastic tumor. Journal of Reproductive Medicine2002;47(5):380‐6. ">Garner 2002</a>; <a href="./references#CD007289-bbs2-0033" title="GarrettLA , GarnerEIO , FeltmateCM . Subsequent pregnancy outcomes in patients with molar pregnancy and persistent gestational trophoblastic neoplasia. Journal of Reproductive Medicine2008;53(7):481‐6. ">Garrett 2008</a>; <a href="./references#CD007289-bbs2-0037" title="GoldsteinDP , BerkowitzRS . Prophylactic chemotherapy of complete molar pregnancy. Seminars in Oncology1995;22(2):157‐60. ">Goldstein 1995</a>; <a href="./references#CD007289-bbs2-0007" title="UbertiEMH , DiestelMCF , GuimarãesFE , DeNapoliG , SchmidH . Single‐dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high‐risk hydatidiform mole. Gynecologic Oncology2006;102:325‐32. [DOI: 10.1016/j.ygyno.2005.12.036] ">Uberti 2006</a>; <a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a>). </p> <p><a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a> has suggested that P‐Chem reduces the emotional complications associated with HM but we were unable to corroborate this owing to a lack of QoL data. </p> </section> <section id="CD007289-sec-0085"> <h4 class="title">Drug resistance</h4> <p>Drug resistance may occur following P‐Chem, as the agents used for P‐Chem are also used as first‐line treatment for GTN. Only one included study compared the number of courses of chemotherapy required to treat subsequent GTN (<a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>). These investigators found that women in the P‐Chem group (4 women) required more courses than women in the control group (10 women), suggesting that P‐Chem may increase resistance to subsequent chemotherapy. Owing to the poor methodological quality of the <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> study and the small number of participants concerned, we are very uncertain of this estimate of effect (<a href="./full#CD007289-tbl-0001">summary of findings Table for the main comparison</a>). To prevent resistance to treatment it has been suggested that an alternative agent be used for the treatment of persistent disease (<a href="./references#CD007289-bbs2-0037" title="GoldsteinDP , BerkowitzRS . Prophylactic chemotherapy of complete molar pregnancy. Seminars in Oncology1995;22(2):157‐60. ">Goldstein 1995</a>). Drug resistance could not be adequately evaluated in this review and warrants further investigation. </p> </section> <section id="CD007289-sec-0086"> <h4 class="title">Time to GTN diagnosis</h4> <p>The time interval from the index pregnancy to the diagnosis of GTN is considered to be a risk factor for the development of GTN and is included in the Modified WHO Prognostic Scoring System (<a href="./references#CD007289-bbs2-0029" title="FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. International Journal of Gynaecology and Obstetrics2009;105(1):3‐4. ">FIGO 2009</a>). Again, extremely limited evidence from <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> suggests that P‐Chem may delay the time to diagnosis of GTN. It is unclear whether such a delay might potentially lead to up‐scoring of GTN lesions from low to high risk. Investigators of some retrospective studies of single‐dose dactinomycin found no difference in the time to GTN diagnosis among their participants (<a href="./references#CD007289-bbs2-0007" title="UbertiEMH , DiestelMCF , GuimarãesFE , DeNapoliG , SchmidH . Single‐dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high‐risk hydatidiform mole. Gynecologic Oncology2006;102:325‐32. [DOI: 10.1016/j.ygyno.2005.12.036] ">Uberti 2006</a>; <a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a>). Thus further research is needed to clarify the impact of low‐dose P‐Chem on the time to diagnosis and subsequent GTN risk scores. </p> </section> <section id="CD007289-sec-0087"> <h4 class="title">Timing of ERPC</h4> <p>Studies of P‐Chem to date have administered P‐Chem before performing the ERPC, with the exception of <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>, <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> and <a href="./references#CD007289-bbs2-0046" title="KogaK , MaedaK . Prophylactic chemotherapy with Amethopterin for prevention of choriocarcinoma following removal of hydatidiform mole. American Journal of Obstetrics and Gynecology1968;100(2):270‐5. ">Koga 1968</a>, where participants received their P‐Chem within 1 week and 3 weeks of the ERPC. Only <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> included participants based on a histological diagnosis. <a href="./references#CD007289-bbs2-0034" title="GoldsteinDP . Prophylactic chemotherapy of patients with molar pregnancy. Obstetrics and Gynecology1971;38(6):817‐22. ">Goldstein 1971</a> was the first to describe performing the ERPC on P‐Chem day 3 (see <a href="#CD007289-tbl-0003">Table 2</a>) and this practice was included in several subsequent studies, including <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>. Administering P‐Chem before ERPC may theoretically be more effective in preventing haematogenous spread of the molar tissue during the procedure. Since the incidence of GTN in the high‐risk groups of <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> and <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a> were similar, it would appear that administering P‐Chem before ERPC may not confer any additional benefit. Treating women with P‐Chem before evacuation carries the inherent risk of over‐treating women, as 10% of cases that are thought to be molar on ultrasound may turn out to be non‐molar hydropic abortions (<a href="./references#CD007289-bbs2-0031" title="FowlerDJ , LindsayI , SecklMJ , SebireNJ . Routine pre‐evacuation ultrasound diagnosis of hydatidiform mole: experience of more than 1000 cases from a regional referral center. Ultrasound in Obstetrics &amp; Gynecology2006;27(1):56‐60. ">Fowler 2006</a>). Thus we propose that in any future studies of P‐Chem, the intervention is administered after ERPC, and following a histological diagnosis of CM. </p> </section> </section> <section id="CD007289-sec-0088"> <h3 class="title" id="CD007289-sec-0088">Quality of the evidence</h3> <p>We consider this evidence to be of low to very low quality. This conclusion is based on our assessment that two of the included studies were of poor methodological quality and at a high risk of bias (See <a href="#CD007289-sec-0062">Risk of bias in included studies</a>); the third study was of good quality but consisted of only 60 participants. <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> and <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> are older studies that took place before rigorous RCT guidelines were in place. </p> <p>With reference to the evidence for high‐risk CMs only, we calculated that the number needed to treat for an additional beneficial outcome (NNTB) to prevent one woman with high‐risk CM developing GTN was 3, with a 95% CI of 2 to 20 women; this wide CI illustrates the uncertainty concerning this evidence. Therefore, we believe that further research is very likely to have an important impact on our confidence in the estimate of effects, and is likely to change the estimates. </p> <p>With regard to the number of courses of chemotherapy required to cure post‐molar GTN, we are very uncertain about this estimate of effect (see <a href="./full#CD007289-tbl-0001">summary of findings Table for the main comparison</a>). </p> </section> <section id="CD007289-sec-0089"> <h3 class="title" id="CD007289-sec-0089">Potential biases in the review process</h3> <p>We included all identified RCTs in this review, including two older studies of poor methodological quality. We rigorously debated the merits of including these weaker studies as, in so doing, we might have biased the results in favour of P‐Chem. In particular, <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> describes the study design as "prospective", with participants "selected at random". While some authors have interpreted this study design as an RCT (<a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>), it has also been referred to as a retrospective study (<a href="./references#CD007289-bbs2-0037" title="GoldsteinDP , BerkowitzRS . Prophylactic chemotherapy of complete molar pregnancy. Seminars in Oncology1995;22(2):157‐60. ">Goldstein 1995</a>). We were unsuccessful in making contact with the investigators of either <a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> or <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> and therefore it was not possible to determine whether these were true RCTs. We decided to include them in our meta‐analyses. This may seem controversial; however, we performed sensitivity analyses and downgraded the meta‐analyses results accordingly. Sensitivity analysis of the main outcome produced similar findings when these studies were excluded. Furthermore, these weaker studies included low‐ and high‐risk women in their sample, which may have biased the results in the direction of the control group, as P‐Chem was found in these studies to have little benefit for women with a low risk of developing GTN. </p> </section> <section id="CD007289-sec-0090"> <h3 class="title" id="CD007289-sec-0090">Agreements and disagreements with other studies or reviews</h3> <p>Most recent studies of P‐Chem have been conducted in Asia and South America. This may be indicative of higher prevalence of GTD, limited health resources or lower rates of follow‐up experienced by women in these regions. However, concerns regarding the exposure of women to unnecessary side effects may have played a role in the lack of contributing data from centres in North America and Europe (<a href="./references#CD007289-bbs2-0037" title="GoldsteinDP , BerkowitzRS . Prophylactic chemotherapy of complete molar pregnancy. Seminars in Oncology1995;22(2):157‐60. ">Goldstein 1995</a>). </p> <p>Most recently, investigators in Brazil conducted two retrospective case‐control studies and reported a significant reduction in the rate of GTN transformation with the use of a single bolus dose of dactinomycin before evacuation for high‐risk HM, with minimal side effects (see <a href="#CD007289-tbl-0003">Table 2</a>; <a href="./references#CD007289-bbs2-0007" title="UbertiEMH , DiestelMCF , GuimarãesFE , DeNapoliG , SchmidH . Single‐dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high‐risk hydatidiform mole. Gynecologic Oncology2006;102:325‐32. [DOI: 10.1016/j.ygyno.2005.12.036] ">Uberti 2006</a>; <a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a>). Baseline risk scores and hCG levels were significantly greater in the P‐Chem arm of the latter study, yet the incidence of GTN was significantly lower in the P‐Chem group compared with the control group. These studies suggest that low‐dose dactinomycin may have an improved effectiveness‐to‐toxicity ratio, and hence greater general acceptability as a P‐Chem regimen. </p> <p>It has been argued that because of the excellent primary cure rates among women with GTN, most doctors prefer to monitor hCG levels in women following HM, rather than administer P‐Chem (<a href="./references#CD007289-bbs2-0044" title="HurteauJ . Gestational trophoblastic disease: management of hydatidiform mole. Clinical Obstetrics and Gynecology2003;46(3):557‐69. ">Hurteau 2003</a>). In addition, even if prophylaxis reduces the risk of GTN, women who are given prophylaxis would still require the same monitoring and follow‐up as those who are not. However, P‐Chem may reduce emotional costs for affected women, as well as operating costs for institutions (<a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a>). In <a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a>, the number of women with high‐risk HM who needed to be treated (NNTB) to prevent one case of GTN was seven; at this rate, P‐Chem would apparently result in substantial cost savings to their GTD centre. Following a personal communication with Dr Uberti, we understand that this regimen is already in clinical practice in this GTD Centre in Brazil. The emotional (QoL) and cost implications of P‐Chem versus no P‐Chem could not be evaluated in this review, </p> <p>P‐Chem may not be the only method of reducing the incidence of GTN. In Japan, second ERPCs are performed within one week of the first ERPC following histological confirmation of HM (<a href="./references#CD007289-bbs2-0057" title="SasakiS , SasakiY . Chapter 15: clinical management of trophoblastic diseases in Japan. In: HancockBW , SecklMJ , BerkowitzRS , ColeLA editor(s). Gestational Trophoblastic Disease. 3rd Edition. London: International Society for the Study of Trophoblastic Diseases, 2009:398‐406. ">Sasaki 2009</a>); and in Indonesia, women with HM are given vitamin A supplementation (personal communication; <a href="./references#CD007289-bbs2-0011" title="AndrijonoM , MuhilalM . Prevention of post‐mole malignant trophoblastic disease with vitamin A. Asian Pacific Journal of Cancer Prevention2010;11(2):567‐70. ">Andrijono 2010</a>). In one double‐blind RCT conducted in Indonesia, vitamin A prophylaxis was compared with an identical placebo in women with CMs (<a href="./references#CD007289-bbs2-0011" title="AndrijonoM , MuhilalM . Prevention of post‐mole malignant trophoblastic disease with vitamin A. Asian Pacific Journal of Cancer Prevention2010;11(2):567‐70. ">Andrijono 2010</a>). The theoretical basis for this intervention was that vitamin A has been shown to cause trophoblastic cells to undergo apoptosis (<a href="./references#CD007289-bbs2-0011" title="AndrijonoM , MuhilalM . Prevention of post‐mole malignant trophoblastic disease with vitamin A. Asian Pacific Journal of Cancer Prevention2010;11(2):567‐70. ">Andrijono 2010</a>). Investigators reported that only 2 out of 30 women (6.7%) with CM who received 200,000 IU of vitamin A per day progressed to GTN compared with 10 out of 35 in the placebo group (28.6%) (P = 0.029). Side effects appeared to have been minimal. The proportion of high‐risk CMs and the median duration of prophylaxis were not reported; however, these results are encouraging and warrant further research into vitamin A supplementation in women with HM. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD007289-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/urn:x-wiley:14651858:media:CD007289:CD007289-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_t/tCD007289-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD007289-fig-0001" src="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007289-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/urn:x-wiley:14651858:media:CD007289:CD007289-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_t/tCD007289-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study." data-id="CD007289-fig-0002" src="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>'Risk of bias' summary: review authors' judgements about each 'Risk of bias' item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007289-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/urn:x-wiley:14651858:media:CD007289:CD007289-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_t/tCD007289-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic chemotherapy versus no prophylactic chemotherapy, Outcome 1 Incidence of GTN (overall)." data-id="CD007289-fig-0003" src="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic chemotherapy versus no prophylactic chemotherapy, Outcome 1 Incidence of GTN (overall). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/references#CD007289-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007289-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/urn:x-wiley:14651858:media:CD007289:CD007289-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_t/tCD007289-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic chemotherapy versus no prophylactic chemotherapy, Outcome 2 Incidence of GTN (high‐risk HM only)." data-id="CD007289-fig-0004" src="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic chemotherapy versus no prophylactic chemotherapy, Outcome 2 Incidence of GTN (high‐risk HM only). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/references#CD007289-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007289-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/urn:x-wiley:14651858:media:CD007289:CD007289-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_t/tCD007289-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic chemotherapy versus no prophylactic chemotherapy, Outcome 3 Time to GTN diagnosis." data-id="CD007289-fig-0005" src="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic chemotherapy versus no prophylactic chemotherapy, Outcome 3 Time to GTN diagnosis. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/references#CD007289-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007289-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/urn:x-wiley:14651858:media:CD007289:CD007289-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_t/tCD007289-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic chemotherapy versus no prophylactic chemotherapy, Outcome 4 Number of courses of chemotherapy to cure." data-id="CD007289-fig-0006" src="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic chemotherapy versus no prophylactic chemotherapy, Outcome 4 Number of courses of chemotherapy to cure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/references#CD007289-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD007289-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/urn:x-wiley:14651858:media:CD007289:CD007289-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_t/tCD007289-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Prophylactic chemotherapy versus no prophylactic chemotherapy, Outcome 5 Mortality rate." data-id="CD007289-fig-0007" src="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Prophylactic chemotherapy versus no prophylactic chemotherapy, Outcome 5 Mortality rate. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/references#CD007289-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/media/CDSR/CD007289/image_n/nCD007289-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD007289-tbl-0001"> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Prophylactic chemotherapy compared with no prophylactic chemotherapy for hydatidiform mole</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population: women with a molar pregnancy</b> </p> <p><b>Settings: inpatient</b> </p> <p><b>Intervention: methotrexate or dactinomycin</b> </p> <p><b>Comparison: placebo or no prophylaxis</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (studies)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>No prophylaxis</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>P‐Chem</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="4" valign="top"> <p><b>Incidence of GTN</b> </p> <p><b>(including low‐quality studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>Mixed‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>RR 0.37</b> (0.24 to 0.57) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>550 women<br/> (3 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p>The NNTB to prevent 1 woman developing GTN after evacuation of HM was 6 (95% CI 5 to 10). We downgraded this evidence because this meta‐analysis included 2 studies that we considered to be of poor methodological quality. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>254 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>94 per 1000</b> (61 to 145) </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.29</b> </p> <p>(0.14 to 0.60)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>99 women</p> <p>(2 studies)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>The NNTB for women with high‐risk HM was 3 (95% CI 2 to 5). We downgraded this evidence because the meta‐analysis included 2 small studies, 1 of which was of a poor methodological quality. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>490 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p>142 per 1000 (69 to 294)</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Incidence of GTN</b> </p> <p><b>(excluding low‐quality studies)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign=""> <p><b>High‐risk population</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>RR 0.28 (</b>0.10 to 0.73) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>59 women</p> <p>(1 study)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>The NNTB to prevent 1 woman developing GTN after evacuation of high‐risk HM was 3 (95% CI 2 to 20). We downgraded this evidence because only 1 small study (<a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>) contributed data, giving an imprecise result. </p> </td> </tr> <tr class="separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>500 per 1000</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign=""> <p><b>140 per 1000</b> (50 to 365) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to GTN diagnosis</b> </p> <p><b>(days)</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to GTN diagnosis ranged across control groups from 35.7 days to 59.5 days. </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean time to GTN diagnosis in the intervention groups was 65.5 days to 81.8 days (higher). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 28.72</b> (13.19 to 44.24) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 women<br/> (2 studies) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We downgraded this evidence because the meta‐analysis included 1 study of poor methodological quality (<a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>). When this study was excluded, the results of the remaining study (<a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>; 19 women) were: MD 22.30; 95% CI −9.05 to 53.65. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Number of courses of chemotherapy to cure</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of courses of chemotherapy required to cure subsequent GTN was 1.4 courses (10 women). </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The mean number of courses of chemotherapy required to cure subsequent GTN was 2.5 courses (4 women). </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>MD 1.10</b> </p> <p>(0.52 to 1.68)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14 women<br/> (1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/> <b>very low</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>This analysis only included 1 study, and we considered to be of a poor methodological quality (<a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI).<br/> CI: confidence interval; HM: hydatidiform mole; NNTB: number needed to treat for an additional beneficial outcome; RR: risk ratio; MD: mean difference; GTN: gestational trophoblastic neoplasia. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>The assumed risk for the mixed‐risk population was calculated by using the weighted mean risk across the control group for this outcome. The assumed risk for the high‐risk population was based on the control group of <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>, which was the only study to evaluate a high‐risk population only. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-title"></span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007289-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk scoring system for the prediction of GTN in women with molar pregnancy*</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p>Prognostic factor</p> </td> <td align="center" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>Score</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>U/S diagnosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Partial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Complete</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Recurrent</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Uterine size for GA (months)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>not more than 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 3</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>hCG level (mIU/mL)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 50,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50,000 to &lt; 100,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 100,000 to &lt; 1,000,000</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 1,000,000</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Diameter of theca lutein cysts (cm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 6 to &lt; 10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 10</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Patient age (years)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&lt; 20</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>&gt; 50</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>Medical complications**</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>≥ 1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>‐</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="5"> <div class="table-footnote"> <p>*From <a href="./references#CD007289-bbs2-0018" title="BerkowitzRS , GoldsteinDP , DubeshterB , BernsteinM . Management of complete molar pregnancy. Journal of Reproductive Medicine1987;32(9):634‐9. ">Berkowitz 1987</a> </p> <p>Low risk is defined as a score of &lt; 4; high risk is defined as a score ≥ 4</p> <p>U/S: ultrasound; GA: gestational age, hCG: β‐human chorionic gonadotrophin.</p> <p>** hyperemesis, hyperthyroidism, pre‐eclampsia, trophoblastic embolisation, disseminated intravascular coagulation. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Risk scoring system for the prediction of GTN in women with molar pregnancy*</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD007289-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparative studies of P‐Chem for hydatidiform mole</span></div> <tbody> <tr> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Study</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Design</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> <p>(P‐Chem)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participants</p> <p>(control/no P‐Chem)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of GTN (P‐Chem)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rate of GTN (control)</p> </td> <td align="center" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comments</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0046" title="KogaK , MaedaK . Prophylactic chemotherapy with Amethopterin for prevention of choriocarcinoma following removal of hydatidiform mole. American Journal of Obstetrics and Gynecology1968;100(2):270‐5. ">Koga 1968</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 women (HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 women (HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methotrexate 10 mg/day PO × 7 days given within 3 weeks of ERPC.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/107 (2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/42 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No choriocarcinoma observed in the P‐Chem group vs 3/42 in the control group. Toxic side effects occurred in 84/107 women, including stomatitis (34/107) and myelosuppression (22/107). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0034" title="GoldsteinDP . Prophylactic chemotherapy of patients with molar pregnancy. Obstetrics and Gynecology1971;38(6):817‐22. ">Goldstein 1971</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 intervention arms: methotrexate 0.3 mg/kg/day × 5 days (20 women); or dactinomycin 9 to 12 μg/kg/day × 5 days (53 women); ERPC on day 3. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6/73</p> <p>(8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/116 (20%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No metastatic disease observed in the P‐Chem groups. P‐Chem well tolerated with minor side effects. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0035" title="GoldsteinDP . Prevention of gestational trophoblastic disease by use of actinomycin D in molar pregnancies. Obstetrics and Gynecology1974;43(4):475‐9. ">Goldstein 1974</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 women (HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>100 women (HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dactinomycin 12 μg/kg/day × 5 days. ERPC on day 3.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/100</p> <p>(2%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16/100</p> <p>(16%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No metastatic disease observed in the P‐Chem group vs 4/100 in the control group (4%). Reversible alopecia occurred in 32% of the P‐Chem group. No serious toxic reactions. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0036" title="GoldsteinDP , BerkowitzRS , BernsteinMR . Management of molar pregnancy. Journal of Reproductive Medicine1981;26(4):208‐12. ">Goldstein 1981</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>174 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>858 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dactinomycin 12 μg/kg/day × 5 days. ERPC on day 3.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/247</p> <p>(4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>160/858 (19%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No metastatic disease observed in the P‐Chem group vs 34/858 (4%) in the control group. This report includes data from <a href="./references#CD007289-bbs2-0035" title="GoldsteinDP . Prevention of gestational trophoblastic disease by use of actinomycin D in molar pregnancies. Obstetrics and Gynecology1974;43(4):475‐9. ">Goldstein 1974</a>. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0027" title="FasoliM , RattiF , FrancheschiS , LaVecchiaC , PecorelliS , MangioniC . Management of gestational trophoblastic disease: results of a cooperative study. Obstetrics and Gynecology1982;60(2):205‐9. ">Fasoli 1982</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104 women (92% CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>250 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methotrexate 10 mg/day PO × 5 days every 3 weeks for 3 cycles.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3/104</p> <p>(3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/250</p> <p>(9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly fewer high‐risk women in the P‐Chem group (1/47) vs the control group (18/126) developed GTN (2% vs 14%; P &lt; 0.05). 2 women had severe myelosuppression and 1 had severe alopecia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT (?)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methotrexate 10 mg/day (IM or PO) for 7 days, within 3 weeks of evacuation.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22/293</p> <p>(7%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23/127</p> <p>(18%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>There were 5 cases of metastatic disease in each group (1.7% vs 3.9%, respectively)</p> <p>27.3% of the P‐Chem group experienced drug‐related side effects including stomatitis (10.3%), nausea/vomiting (6.8%) and leukopenia (4.4%). However none were reported to be severe. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0002" title="KimDS , MoonH , KimKT , MoonYJ , HwangYY . Effects of prophylactic chemotherapy for persistent trophoblastic disease in patients with complete hydatidiform mole. Obstetrics and Gynecology1986;67(5):690‐4. ">Kim 1986</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39/71 women (CM; 18/31 low‐risk and 21/40 high‐risk women)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 women (CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methotrexate 1.0 mg/kg/day IM (days 1, 3, 5, 7) and citrovorum factor rescue 0.1 mg/kg/day IM (days 2, 4, 6, 8). ERPC on day 3. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/39 (10%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10/32 (31%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly fewer high‐risk women in the P‐Chem group (14%) vs the control group (47%) developed GTN. There was no significant difference in the GTN rates of low‐risk women between groups. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0054" title="ParkTK , KimSN , LeeSK . Analysis of risk factors for postmolar trophoblastic disease: categorization of risk factors and effect of prophylactic chemotherapy. Yonsei Medical Journal1996;37(6):412‐9. ">Park 1996</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 women (14 low‐risk, 21 medium‐risk and 17 high‐risk HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88 women</p> <p>(38 low‐risk, 25 medium‐risk and 25 high‐risk HM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Methotrexate 1 mg/kg (days 1, 3, 5, 7) and citrovorum factor (0.1 mg/kg (days 2, 4, 6, 8); or dactinomycin 12 μg/kg/day × 5 days started at the time of ERPC. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8/52</p> <p>(15.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28/88 (31.8%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Significantly fewer high‐risk women in the P‐Chem group (7/17) vs the control group (22/25) developed GTN (41% vs 88%; P &lt; 0.01). There was no significant difference in the GTN rates in low‐ and medium‐risk women between groups. The time to achieve normal hCG levels was shorter in high‐risk women in the P‐Chem group. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>* </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Double‐blind RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 women (high‐risk CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 women (high risk CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dactinomycin 10 µg/kg for 5 days, within 1 week after ERPC and histology.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4/29</p> <p>(15.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15/30</p> <p>(50%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild, reversible side effects reported including stomatitis (10%), nausea/vomiting (10%), oral ulcers (3.3%) and hair loss (13.3%) ‒ all grade 1 except for 2 women with grade 2 patchy alopecia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0007" title="UbertiEMH , DiestelMCF , GuimarãesFE , DeNapoliG , SchmidH . Single‐dose actinomycin D: efficacy in the prophylaxis of post molar gestational trophoblastic neoplasia in adolescents with high‐risk hydatidiform mole. Gynecologic Oncology2006;102:325‐32. [DOI: 10.1016/j.ygyno.2005.12.036] ">Uberti 2006</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29 adolescents</p> <p>(high‐risk CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 adolescents</p> <p>(high‐risk CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dactinomycin 1.25 mg/m² IV given 1 hour before ERPC.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/29</p> <p>(6.9%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9/31</p> <p>(29%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mean risk scores and hCG levels were significantly higher and gestational age was significantly lower in the P‐Chem group than the control group. Mild and transient side effects included hepatotoxicity (10%) and mild alopecia (6.8%). </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD007289-bbs2-0008" title="UbertiEMH , FajardoMC , FerreiraSVVR , PereiraMV , SegerRC , MoreiraMAR , et al. Reproductive outcome after discharge of patients with high‐risk hydatidiform mole with or without use of one bolus dose of actinomycin D, as prophylactic chemotherapy, during the uterine evacuation of molar pregnancy. Gynecologic Oncology2009;115(3):476‐81. UbertiEMH , FajardoMC , daCunhaAGV , RosaMW , AyubACK , GraudenzMS , et al. Prevention of post molar gestational trophoblastic neoplasia using prophylactic single bolus dose of actinomycin D in high‐risk hydatidiform mole: a simple, effective, secure and low‐cost approach without adverse effects on compliance to general follow‐up or subsequent treatment. Gynecologic Oncology2009;114(2):299‐305. ">Uberti 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective case‐control</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163 women</p> <p>(high risk, &gt; 90% CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102 women</p> <p>(high risk, &gt; 90% CM)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dactinomycin 1.25 mg/m² IV given 1 hour before ERPC.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30/163 (18.4%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35/102 (34.3%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild and transient side effects including nausea (8%), raised liver enzymes (3.7%), stomatitis (3.1%), rash (2.4%) diarrhoea (2.4%), alopecia (1.2%) and neutropenia (0.6%) were seen in 21% of the P‐Chem group. Time to GTN diagnosis, subsequent drug resistance and the number of chemotherapy course to cure was similar in the 2 groups. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="8"> <div class="table-footnote"> <p>* Three studies administered P‐Chem after ERPC including <a href="./references#CD007289-bbs2-0046" title="KogaK , MaedaK . Prophylactic chemotherapy with Amethopterin for prevention of choriocarcinoma following removal of hydatidiform mole. American Journal of Obstetrics and Gynecology1968;100(2):270‐5. ">Koga 1968</a>, <a href="./references#CD007289-bbs2-0001" title="KashimuraY , KashimuraM , SugimoriH , TsukamotoN , MatsuyamaT , MatsukumaK , et al. Prophylactic chemotherapy for hydatidiform mole: five to 15 years follow up. Cancer1986;58(3):624‐9. ">Kashimura 1986</a> and <a href="./references#CD007289-bbs2-0003" title="LimpongsanurakS . Prophylactic actinomycin D for high‐risk complete hydatidiform mole. Journal of Reproductive Medicine2001;46(2):110‐6. ">Limpongsanurak 2001</a>. </p> <p>CM; complete mole; ERPC: evacuation of retained products of conception; GTN: gestational trophoblastic neoplasia; HM: hydatidiform mole; IM: intramuscular; IV: intravenous; P‐Chem; prophylactic chemotherapy; PO: per os; RCT: randomised controlled trial. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Comparative studies of P‐Chem for hydatidiform mole</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/full#CD007289-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD007289-tbl-0004"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Prophylactic chemotherapy versus no prophylactic chemotherapy</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Incidence of GTN (overall) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>550</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.37 [0.24, 0.57]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.1 Methotrexate prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>491</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.24, 0.64]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.2 Dactinomycin prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.10, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Incidence of GTN (high‐risk HM only) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>99</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.29 [0.14, 0.60]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.1 Methotrexate prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>40</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.30 [0.10, 0.95]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>2.2 Dactinomycin prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.28 [0.10, 0.73]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Time to GTN diagnosis <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>33</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>28.72 [13.19, 44.24]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.1 Methotrexate prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>30.80 [12.93, 48.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>3.2 Dactinomycin prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>19</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>22.30 [‐9.05, 53.65]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Number of courses of chemotherapy to cure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Methotrexate prophylaxis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Mean Difference (IV, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.1 [0.52, 1.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Mortality rate <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Prophylactic chemotherapy versus no prophylactic chemotherapy</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD007289.pub3/references#CD007289-tbl-0004">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD007289.pub3&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD007289-note-0005">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD007289-note-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="hr#CD007289-note-0003">Hrvatski</a> </li> <li class="section-language"> <a class="" href="ja#CD007289-note-0011">日本語</a> </li> <li class="section-language"> <a class="" href="ko#CD007289-note-0001">한국어</a> </li> <li class="section-language"> <a class="" href="ms#CD007289-note-0002">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007289\x2epub3"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007289\x2epub3"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007289\x2epub3"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD007289\x2epub3\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD007289\x2epub3"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=1ljSZou6&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007289.pub3&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD007289.pub3';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD007289.pub3/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD007289.pub3/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD007289.pub3%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728546532"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007289.pub3/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728546535"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD007289.pub3/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ec7202dd6f431',t:'MTc0MDcyODU0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 